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Abstract 
 
Adrenoleukodystrophy (ALD) is an X-linked genetic disorder which affects the adrenal 
glands, peripheral neuronal system, the spinal cord and white matter of central nervous 
system (CNS). It is a progressive neurology disorder with incidence of 1 in 17,000 
newborns. ALD is caused by mutations in the ABCD1 gene, which encodes the 
peroxisomal membrane transporter for transporting very long chain fatty acids (VLCFAs) 
into peroxisomes for degradation. As a result, VLCFAs accumulate in the plasma and 
tissues of ALD patients. Elevated VLCFAs along with ABCD1 gene mutations are used 
for the diagnosis of ALD.  
 
ALD has various clinical phenotypes. Childhood cerebral adrenoleukodystrophy 
(CCALD) is the cerebral form of ALD that affects young boys (4~10 years of age), 
causing progressive, debilitating effects on the CNS leading to death within a few years.  
 
The pathophysiology of CCALD is only partially understood, but it is known that 
VLCFAs accumulate in the plasma, brain and other tissues in CCALD patients, which 
can cause oxidative stress and downstream neurodegeneration. Recently, oxidative stress, 
the accumulation of free radicals (reactive molecules), has been shown to cause CNS 
neurodegeneration and play a major role in CCALD pathophysiology.  
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Currently, the most successful treatment for CCALD is hematopoietic stem cell 
transplantation (HSCT), which halts disease progression and extends life when CCALD 
is treated early. But it is much less effective for late-stage CCALD. Based on evidence 
that oxidative stress plays a role in the disease, the Blood and Marrow transplantation 
group at University of Minnesota has utilized N-acetylcysteine (NAC) as adjunctive 
therapy together with HSCT in late-stage CCALD. This combinatorial approach has 
improved survival rate from 36% to 84% compared to HSCT only in a cohort study 
(Miller et al., 2011). However, NAC’s mechanisms of action are still unclear in CCALD 
patients.  
 
As an FDA-approved drug, NAC is used as an antidote for acetaminophen overdose and 
as a mucolytic agent to reduce symptoms associated with cystic fibrosis. It has gained 
renewed attention as a potential therapy for a number of conditions including pulmonary, 
neurological, psychiatric, and cardiovascular diseases. With a long history of clinical use, 
several mechanisms including antioxidative and anti-inflammatory activities have been 
proposed as the basis for its therapeutic effects. However, the exact molecular mechanism 
by which NAC improves the survival rate of CCALD patients is still unclear. And this 
missing piece of information, which is the basis for my research work, is required to 
further optimize the therapy.  
 
In my thesis, four research projects were designed and implemented to address the 
pharmacology of NAC in CCALD related biological models. The first study was to 
  vi 
investigate the downstream signaling molecules induced by NAC in the plasma of 
CCALD patients. Heme oxygenase-1 (HO-1) and ferritin were examined in CCALD 
patients before and after NAC exposure. Based on the clinical study results that the 
expression of HO-1 and downstream ferritin were induced by NAC, the second study was 
further designed in oligodendrocytes, which are CNS glial cells and closely related to 
demyelination and neurodegneration, to investigate the cytoprotective role of HO-1 
induced by NAC. Moreover, we also tried to delineate the role of accumulation of 
VLCFAs in CCALD and its relationship with oxidative stress and mitochondria. The 
third study was designed in oligodendrocytes to investigate whether mitochondria and 
oxidative stress status are affected by pathophysiological concentrations of VLCFAs and 
if so, whether NAC could be used to reverse this condition. Finally, the fourth 
pharmacokinetic/pharmacodynamics study was designed and implemented in wild-type 
mice to address the relationship between NAC concentration and pharmacodynamic 
endpoints in vivo. This study is also critical to determine the biotransformation of NAC in 
vivo. 
 
The results from my studies indicate HO-1 as the newly discovered downstream 
mediators for NAC action. Studies also show for the first time that depletion of 
mitochondrial glutathione (mtGSH) is the pathological cause for CCALD, and that 
targeting mitochondrial dysfunction can be a potential effective intervention for CCALD 
patients. In addition, GSH levels, redox ratio, HO-1 and ferritin levels can serve as 
biomarkers or pharmacodynamic endpoints to evaluate NAC efficacy.  
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In the long term, characterization of NAC mechanisms of action will help to optimize 
therapy in CCALD patients. In addition, the information generated from my studies on 
the efficacy of NAC in CCALD is also applicable to other neurodegenerative disorders 
sharing similar pathologies such as Gaucher's disease, multiple Sclerosis, Alzheimer's 
disease etc. 
  viii 
Table of Contents 
 
Acknowledgements .............................................................................................................. i 
Dedication .......................................................................................................................... iii 
Abstract .............................................................................................................................. iv 
List of Tables ................................................................................................................... xiv 
List of Figures ................................................................................................................... xv 
List of Abbreviations ..................................................................................................... xviii 
 
CHAPTER 1 INTRODUCTION ........................................................................................ 1 
1.1 Neurodegenerative disorders and oxidative stress ................................................... 2 
1.1.1 Neurodegenerative disorder: epidemiology, pathology and current treatment 
options  .......................................................................................................................... 2 
Epidemiology and influence ........................................................................................ 2 
Pathology ..................................................................................................................... 3 
Treatment challenges ................................................................................................... 4 
1.1.2 Oxidative stress in neurodegenerative disorder ................................................ 6 
Free radicals related to oxidative stress ......................................................................... 6 
Endogenous antioxidants in brain .................................................................................. 7 
A scheme for oxidative stress .......................................................................................... 7 
Damage caused by oxidative stress and related biomarkers .......................................... 9 
Cause and effect relationship between oxidative stress and neurodegeneration.......... 11 
1.1.3 Antioxidant therapy in neurodegenerative diseases ....................................... 12 
1.2 Adrenoleukodystrophy ........................................................................................... 15 
1.2.1 Definition, cause, clinical manifestation, pathology and current treatment 
options  ........................................................................................................................ 15 
1.2.2 Diagnosis, clinical phenotypes and disease progression stages ..................... 16 
1.2.3 The role of oxidative stress in ALD ............................................................... 19 
1.2.4 Treatment options and hematopoietic stem cell transplantation (HSCT) ....... 20 
  ix 
1.3 N-acetylcysteine ..................................................................................................... 22 
1.3.1 History and status, indications and therapeutic applications .......................... 22 
1.3.2 Physical-chemical properties .......................................................................... 23 
1.3.3 Pharmacokinetics ............................................................................................ 24 
Absorption and disposition ........................................................................................ 24 
Metabolism and biotransformation ........................................................................... 25 
Elimination ................................................................................................................ 26 
1.3.4 Pharmacology ................................................................................................. 27 
1.3.5 Side effects and adverse responses ................................................................. 28 
 
CHAPTER 2 RESEARCH RATIONALE, SCOPE AND GENERAL APPROACHES .....  
 ................................................................................................................................ 30 
2.1 Hypothesis and specific aims ................................................................................. 31 
2.2 General approaches for research ............................................................................ 32 
2.2.1 Disease-related pharmacological models ....................................................... 32 
In-vitro models .............................................................................................................. 33 
In-vivo models ............................................................................................................... 33 
Clinical samples ............................................................................................................ 34 
2.2.2 Pharmacokinetic-pharmacodynamic modeling .............................................. 35 
PK/PD models ............................................................................................................... 36 
Population PK/PD modeling ......................................................................................... 38 
2.3 My roles in projects ............................................................................................... 40 
 
CHAPTER 3 NAC THERAPY INCREASED PLASMA CONCENTRATIONS OF 
HEME OXYGENASE-1 IN CCALD PATIENTS ........................................................... 42 
3.1 Introduction ............................................................................................................ 43 
3.2 Methods.................................................................................................................. 45 
3.2.1 Demographics of patients, NAC dosing and blood sampling ........................ 45 
3.2.2 Determination of plasma HO-1 concentrations .............................................. 47 
3.2.3 Determination of plasma ferritin concentrations ............................................ 47 
  x 
3.2.4 In-vitro cell culture ......................................................................................... 48 
3.2.5 Real time PCR ................................................................................................ 48 
3.2.6 Determination of HO-1 concentrations in cell lysates .................................... 49 
3.2.7 Statistical Analysis ......................................................................................... 50 
3.3 Results .................................................................................................................... 50 
3.3.1 Demographics of CCALD patients ................................................................. 50 
3.3.2 NAC increases plasma concentrations of HO-1 and ferritin in CCALD 
patients prior to HSCT .................................................................................................. 51 
3.3.3 Plasma concentrations of HO-1 and ferritin prior to HSCT are highly 
correlated ....................................................................................................................... 52 
3.3.4 Plasma concentrations of HO-1 and ferritin prior and after HSCT procedures .  
  ........................................................................................................................ 53 
3.3.5 NAC increases HO-1 mRNA and protein levels in human fibroblasts .......... 55 
3.4 Discussion .............................................................................................................. 57 
3.5 Conclusion ............................................................................................................. 60 
 
CHAPTER 4 N-ACETYLCYSTEINE PROVIDES CYTOPROTECTION IN MURINE 
OLIGODENDROCYTES THROUGH HEME OXYGENASE-1 ACTIVITY ............... 62 
4.1 Introduction ............................................................................................................ 63 
4.2 Materials and methods ........................................................................................... 64 
4.2.1 Materials ......................................................................................................... 64 
4.2.2 Cell culture and experimental conditions ....................................................... 65 
4.2.3 Cell survival assays ........................................................................................ 66 
4.2.4 Evaluation of intracellular ROS ..................................................................... 66 
4.2.5 Determination of intracellular GSH ............................................................... 67 
4.2.6 Total antioxidant capacity assay ..................................................................... 68 
4.2.7 Statistical data analysis ................................................................................... 69 
4.3 Results .................................................................................................................... 69 
4.3.1 N-acetylcysteine  decreases ROS formation in oligodendrocytes under 
conditions of oxidative stress ........................................................................................ 69 
  xi 
4.3.2 Incubation with NAC improved cell survival in a concentration-dependent 
manner  ........................................................................................................................ 71 
4.3.3 Improved cell survival is attained by increase in intracellular total GSH levels  
   ....................................................................................................................... 74 
4.3.4 Inhibition of GSH synthesis blocked cytoprotective effects of NAC ............ 76 
4.3.5 Heme oxygenase-1 is a potential mediator of the cytoprotective effects of 
NAC  ........................................................................................................................ 78 
4.4 Discussion .............................................................................................................. 82 
4.5 Conclusions ............................................................................................................ 86 
 
CHAPTER 5 N-ACETYLCYSTEINE REVERSES MITOCHONDRIAL TOXICITY OF 
VERY LONG CHAIN FATTY ACIDS IN MURINE OLIDODENDROCYTES .......... 87 
5.1 Introduction ............................................................................................................ 88 
5.2 Materials and methods ........................................................................................... 90 
5.2.1 Materials ......................................................................................................... 90 
5.2.2 Cell culture and treatments ............................................................................. 91 
5.2.3 Cell survival assays ........................................................................................ 91 
5.2.4 Evaluation of intracellular ROS ..................................................................... 91 
5.2.5 Determination of intracellular GSH ............................................................... 92 
5.2.6 Mitochondrial inner membrane potential ....................................................... 93 
5.2.7 Mitochondrial superoxide levels .................................................................... 93 
5.2.8 Mitochondrial GSH (mtGSH) levels .............................................................. 94 
5.2.9 ATP production analysis ................................................................................ 94 
5.2.10 Statistical analysis........................................................................................... 95 
5.3 Results .................................................................................................................... 95 
5.3.1 VLCFAs reduce cell survival and ATP production........................................ 95 
5.3.2 VLCFAs do not cause significant changes in cellular oxidative stress .......... 97 
5.3.3 VLCFAs deplete mtGSH, affect mitochondrial redox balance and induce 
mitochondrial depolarization......................................................................................... 98 
5.3.4 Effect of NAC treatment on VLCFA induced mitochondrial toxicity ......... 103 
  xii 
5.3.5 VLCFAs Increase the Sensitivity to Chemical Oxidants in 158N 
Oligodendrocytes ........................................................................................................ 105 
5.4 Discussion ............................................................................................................ 108 
5.5 Conclusion ........................................................................................................... 112 
 
CHAPTER 6 A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF N-
ACETYLCYSTEINE TO UNDERSTAND ITS EFFECT ON BRAIN AND BLOOD 
GLUTATHIONE STATUS IN WILD-TYPE MICE ..................................................... 114 
6.1 Introduction .......................................................................................................... 115 
6.2 Materials and Methods:........................................................................................ 118 
6.2.1 Materials ....................................................................................................... 118 
6.2.2 Subjects ......................................................................................................... 119 
6.2.3 NAC intravenous formulation ...................................................................... 119 
6.2.4 Drug administration ...................................................................................... 120 
6.2.5 Sampling methods ........................................................................................ 121 
6.2.6 Plasma/RBC/brain sample processing methods ........................................... 121 
6.2.7 Analytical methods ....................................................................................... 122 
6.2.8 Treatment of NAC Plasma Concentrations below the Limit of Quantification 
(BLQ)  ...................................................................................................................... 124 
6.2.9 Non-compartmental PK analysis .................................................................. 124 
6.2.10 Population pharmacokinetic/pharmacodynamic analysis ............................. 125 
6.2.11 Model evaluation .......................................................................................... 129 
6.3 Results .................................................................................................................. 129 
6.3.1 Non-compartmental PK analysis of NAC in wild type (WT) mice ............. 129 
6.3.2 Compartmental population analysis of NAC in WT mice ........................... 131 
6.3.3 Labeled NAC boosts unlabeled GSH rather than labeled GSH in RBC ...... 134 
6.3.4 Population PK/PD analysis of NAC in plasma and total GSH in RBC ....... 137 
6.3.5 Labeled NAC boosts redox ratios of unlabeled GSH/GSSG in brain .......... 140 
6.4 Discussion ............................................................................................................ 142 
6.5 Conclusion ........................................................................................................... 146 
 
  xiii 
CHAPTER 7 ................................................................................................................... 148 
CONCLUSIONS AND FUTURE STUDIES ................................................................. 148 
7.1 Summary and conclusions ................................................................................... 149 
7.2 Significance.......................................................................................................... 151 
7.3 Future studies ....................................................................................................... 152 
 
REFERENCES ............................................................................................................... 154 
 
  xiv 
List of Tables 
 
Table 1-1 Selected studies of antioxidant therapy in neurodegeneration......................... 13 
Table 6-1 NAC PK parameters estimated by three different NCA methods in WT mice ...... 
......................................................................................................................................... 131 
Table 6-2 Final PK parameter estimates obtained from 2-compartmental model for 
intravenous NAC in WT mice .......................................................................................... 132 
Table 6-3 NAC-GSH population PD parameters in WT mice estimated in ADAPT5. ... 138 
  
 
  xv 
List of Figures 
 
Figure 1-1 Oxidative stress is caused by either increased free radicals or decreased 
antioxidants ......................................................................................................................... 8 
Figure 1-2 Mutations in ABCD1 gene cause adrenoleukodystrophy................................ 16 
Figure 1-3 Chemical structure of NAC ............................................................................. 23 
Figure 1-4 Biotransformation of NAC .............................................................................. 26 
Figure 2-1 Hypothesis for research .................................................................................. 31 
Figure 2-2 Basic components of Pharmacodynamic models of drug action. ................... 37 
Figure 3-1 HSCT procedure with NAC adjuvant therapy for CCALD patients ............... 46 
Figure 3-2 Plasma HO-1(A) and ferritin (B) levels in plasma samples from CCALD 
patients increased significantly before and after NAC treatment  .................................... 51 
Figure 3-3 Correlation between plasma HO-1 and plasma ferritin in CCALD patients for 
PRE-NAC and POST-NAC-1 samples prior to HSCT. ..................................................... 53 
Figure 3-4 HO-1(A) and ferritin (B) levels in plasma samples from CCALD patients prior 
to and after HSCT procedure ............................................................................................ 55 
Figure 3-5 HO-1 expression (mRNA and protein levels) in human fibroblast cell line 
following NAC treatment. ................................................................................................. 56 
Figure 4-1 Incubation with NAC decreased ROS in 158N (A, exogenous ROS) and 158JP 
(B, endogenous ROS) cells ................................................................................................ 70 
Figure 4-2 NAC augmented cell survival under conditions of oxidative stress in a 
concentration dependent manner ...................................................................................... 73 
Figure 4-3 LC-MS analysis of intracellular reduced form of GSH in 158N (A) and 158JP 
cells (B) ............................................................................................................................. 75 
Figure 4-4 Inhibition of GSH synthesis blocked cytoprotective effects of NAC ............... 77 
Figure 4-5 HO-1 plays a vital role in the cytoprotective action of NAC .......................... 79 
Figure 4-6 Total antioxidant capacity (TAC) assays in presence of HO-1 activity inhibitor 
(CrMP) .............................................................................................................................. 81 
  xvi 
Figure 5-1 C26:0 reduced cell survival (A) and ATP production (B) in a concentration 
dependent manner. ............................................................................................................ 96 
Figure 5-2 ROS levels in 158N cells after incubation with C26:0 and NAC for 24 hrs 
were measured .................................................................................................................. 97 
Figure 5-3 Total intracellualr GSH (A) and mtGSH levels (B) in 158N cells were 
measured after incubation with C26:0 and NAC for 24 hrs ............................................. 99 
Figure 5-4 C26:0 increased mitochondrial superoxide levels and NAC decreased the 
levels ............................................................................................................................... 100 
Figure 5-5 C26:0 decreased mitochondrial inner membrane potential (ΔΨm) and NAC 
alleviated this effect. ....................................................................................................... 102 
Figure 5-6 Bar plot indicated quantification of JC-1 fluorescence in 96-well plates .... 103 
Figure 5-7 C26:0 increased sensitivity to acrolein in 158N cells. .................................. 107 
Figure 5-8 Hypothesized model depicting first hit by C26:0 which depletes mtGSH. .... 112 
Figure 6-1 Structure of stable-labeled 15N-Acetyl(13C3) L-Cysteine and 
biotransformation pathways of NAC into GSH. ............................................................. 117 
Figure 6-2 LC/MS chromatography of stable-labeled NAC (A , B) and unlabeled NAC (C, 
D). ................................................................................................................................... 120 
Figure 6-3 Structure of the PK-PD model for NAC-GSH ............................................... 128 
Figure 6-4 Plasma NAC concentration- time profile in WT mice after application of BLQ 
rules................................................................................................................................. 130 
Figure 6-5 Goodness-of-fit graphics for NAC plasma concentration fitted with 2-
compartmental PK model ............................................................................................... 133 
Figure 6-6 Visual predictive check (VPC) for NAC plasma concentration fitted with 2-
compartmental PK model. .............................................................................................. 134 
Figure 6-7 Unlabeled(A) and labeled total GSH(B) levels detected in the RBC following 
NAC dosing in WT mice .................................................................................................. 136 
Figure 6-8 Goodness-of-fit graphics for PD output (GSH in RBC) of NAC-GSH PK/PD 
modeling .......................................................................................................................... 139 
Figure 6-9 Visual predictive check (VPC) plots for NAC-GSH PK-PD model evaluation
......................................................................................................................................... 140 
  xvii 
Figure 6-10 Redox ratios (GSH/GSSG) in the brain post NAC dosing in WT mice ....... 141 
Figure 6-11 Basic indirect response model structure and representative response variable 
time profile . .................................................................................................................... 145 
 
 
 
 
 
 
  xviii 
List of Abbreviations 
 
ALD: Adrenoleukodystrophy 
AMN: Adrenomyeloneuropathy 
aGVHD: acute graft-versus-host disease  
BSO: L-buthionine-(S,R)-sulfoximine 
BBB: Blood-brain-barrier 
CCALD: Childhood cerebral adrenoleukodystrophy 
CrMP: Chromium mesoporphyrin IX chloride 
CO: Carbon monoxide 
CNS: Central nervous system  
FACS: Fluorescence-activated cell sorting 
GSH: Glutathione 
HO-1: Heme oxygenase-1 
HSCT: hematopoietic stem cell transplantation 
JP: Jimpy  
mtGSH: Mitochondrial glutathione  
NAC: N-acetylcysteine 
N: Normal 
NCA: Non-compartmental analysis 
PK: Pharmacokinetic 
PD: Pharmacodynamic 
  xviii 
ROS: Reactive oxygen species 
RNS: Reactive nitrogen species 
Redox: Reduction-oxidation 
TAC: Total antioxidant capacity 
VLCFAs: very long chain fatty acids 
WT: wild type
  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
  2 
1.1  Neurodegenerative disorders and oxidative stress 
 
Neurodegenerative disorders are a heterogeneous group of diseases characterized by 
selective loss of neurons and progressive neuronal dysfunction. Prototype examples of 
neurodegenerative disorders with central nervous system (CNS) dysfunction include 
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, 
Gaucher’s disease and Adrenoleukodystrophy (ALD) etc. Despite the heterogeneity in 
clinical manifestations and genetic origins, this group of neurodegenerative diseases may 
share common pathological mechanisms, resulting in neuronal cell death. Accumulations 
of insoluble biomolecules such as misfolded proteins or very long chain fatty acids 
(VLCFAs), mitochondria dysfunction and oxidative stress, as well as neuroinflammation 
(Lin and Beal, 2006, Skovronsky et al., 2006, Frank-Cannon et al., 2009) were 
demonstrated over the past few years as the common motifs in neurodegenerative 
disorders. Among all others, oxidative stress was thought to be the early event during the 
neurodegenerative process (Frank-Cannon et al., 2009). The relationship between 
neurodegeneration and oxidative stress, as well as antioxidant therapeutic strategies will 
be discussed in this section.   
 
1.1.1 Neurodegenerative disorder: epidemiology, pathology and current 
treatment options 
 
Epidemiology and influence 
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Neurodegenerative disorders account for a significant proportion of morbidity and 
mortality of  U.S. populations, e.g. the average incidence of Parkinson’s disease was 
estimated as 13.4 per 100,000 per year (Van Den Eeden et al., 2003), and it is expected 1 
out 45 Americans will be affected by Alzheimer’s Disease by 2040 (Reitz and Mayeux, 
2010). Moreover, these disorders cost the U.S. country billions of dollars a year, e.g. an 
estimate of over $100 billion per year is attributed to the direct cost on Alzheimer’s 
disease alone (Meek et al., 1998). In addition, there is tremendous physical and emotional 
burden on the society. Thus an investigation for efficient therapies to treat 
neurodegenerative disorder is quite necessary. Given that neurodegenerative disorders 
share the common characteristic of progressive loss of functional neuron cells, 
investigating mechanisms causing neuronal cell death is critical to provide valuable 
insights for therapeutics discovery and development. In this thesis, I will focus on 
deciphering the toxicological mechanisms in ALD resulting in cell death and examining 
the efficacy of potential antioxidants. This piece of information hopefully can be applied 
to other neurodegenerative disorders with similar pathologies. 
 
Pathology 
 
 
Two major known risk factors associated with neurodegenerative disorders are genetic 
polymorphisms and environmental factors. Genetic mutations are identified in certain 
patient populations, e.g. Gaucher’s disease is caused by mutations in the 
glucocerebrosidase gene that encodes the critical lysosomal enzyme for degradation of  
glucocerebroside (Bennett and Mohan, 2013); and mutations in amyloid precursor protein 
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are closely related to familial forms of Alzheimer’s disease (Maltsev et al., 2013). Many 
of the neurodegenerative diseases are rare and caused by genetic mutations. However, 
environmental factors such as aging and oxidative stress are also crucial in 
neurodegenerative disease progression. In addition, other possible environmental factors 
include gender, social factors, psychological factors, inflammation, infection, tumors, 
chemical exposure, endocrine levels or physiological conditions. These environmental 
factors could influence the time for disease onset, severity of the disease and speed of 
disease progression. Environmental factors have been demonstrated to play an important 
role in neurodegenerative disorders (Brown et al., 2005). It is quite possible that both 
environmental and genetic risk factors synergistically accelerate the neurodegeneration 
process (Peng et al., 2010).   
 
 Treatment challenges 
 
 
Many neurodegenerative diseases are associated with dysfunction in CNS. Although it 
seems necessary to deliver drugs into the brain, challenges of drug delivery arise due to 
blood-brain-barrier (BBB). BBB is a tightly regulated barrier across the CNS. It is 
composed of a layer of endothelial cells with tight junctions surrounding by astrocytes. 
Only necessary nutrients come across the brain, through passive diffusion in the case of 
non-polar small molecule, or through selective transporters. For example, glucose is 
transported through the BBB via GLUT family transporters (Pardridge et al., 1990). 
However, the tight junctions of BBB prevent the penetration of most hydrophilic drug 
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molecules. In addition, BBB is equipped with active transporters such as P-glycoprotein 
(PgP), acting in the reverse direction to export selective molecules. Optimal drug 
molecules (or its active metabolites) for neurodegenerative disorders are expected to have 
the potential to come across the BBB and elicit its efficacy at the site of brain. And, 
reports have shown that the structure of BBB is still intact in neurodegenerative disorders 
such as Parkinson’s and Alzheimer’s disorders (Desai et al., 2007). In such scenarios, the 
efficacy of the drug molecule is directly linked to the active metabolite concentration in 
the brain rather than in the plasma. Pharamcokinetic/ pharmacodynamic (PK/PD) 
modeling, a mathematical model describing the relationship between plasma 
concentrations and efficacy in the brain, could greatly facilitate the understanding of drug 
mechanisms. 
 
Another major challenge is the unclear disease pathology, as well as lack of reliable 
evaluation parameters for neurodegenerative diseases. Clinical performance including 
various scales of disease evaluation is the golden standard for clinical trial evaluation. 
However, these scales are within a limited range and usually insensitive to the modest 
changes in early phase of disease progression (Stocchi and Olanow, 2013). Therefore, 
simple, inexpensive, reliable, rapidly obtainable, well-defined biomarkers are necessary 
to facilitate diagnosis, prognosis, therapy, disease monitoring and drug development 
(Feigin, 2004). In addition, the US Food and Drug Administration (FDA) could possibly 
accept biomarkers as clinical endpoints in drug application as long as the biomarkers are 
“reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other 
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evidence, to predict clinical benefit” (Biomarkers-Definitions-Working-Group, 2001). 
Based on these promising applications of biomarkers, a lot of efforts have been made to 
achieve reliable biomarkers to evaluate the efficacy of drug candidates and disease 
progression. For example, the project of “Parkinson’s Progression Markers Initiative 
(PPMI)” is in progress to identify biomarkers related to Parkinson’s disease (PPMI, 
2011). Other biomarkers related to ALD have also been reported for drug monitoring and 
treatment of disease (Orchard et al., 2011).  GSH level is also reported to be a valuable 
biomarker for NAC efficacy in Parkinson’s and Gaucher’s patients (Holmay et al., 2013). 
Validated biomarkers, of which the change can be detected early and parallel to disease 
progression, are quite important in finding new treatments to neurodegenerative 
disorders. 
 
1.1.2 Oxidative stress in neurodegenerative disorder 
       
Free radicals related to oxidative stress 
 
Oxidative stress arises from imbalanced reduction-oxidation (redox) regulation in 
biological systems. Oxidative stress involves free radicals such as reactive oxygen 
species (ROS) and reactive nitrogen species (RNS).  95% of ROS is produced through 
the mitochondrial respiratory chain as byproducts of O2 consumption and ATP generation 
(Emerit et al., 2004). ROS species mainly include super oxide anion (O
2-
) and H2O2, and 
RNS species originate from the gaseous messenger nitric oxide (NO). NO reacts rapidly 
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with O
2-
 to form peroxynitrite (ONOO
-
), which is a highly reactive oxidant. ROS and 
RNS are produced in large amounts in disease conditions and are thought to be highly 
related to neuronal cell death in neurodegenerative diseases (Calabrese et al., 2005). 
 
 Endogenous antioxidants in brain 
 
The brain utilizes an antioxidant system to defend against oxidative stress as well as 
possible related detrimental effects. This complicated self-defense system includes 
enzymes such as superoxide dismutases, glutathione peroxidase, glutathione reductase, 
glutathione S-transferase, catalase and peroxiredoxins; small molecule antioxidants such 
as GSH, cysteine, ascorbate, α-tocopherol and ubiquinol; or metal-binding related 
protective proteins such as metallothionein, heme oxygenase-1 and ferritin (Halliwell, 
2001). Levels of these endogenous antioxidants are closely modulated in biological 
systems to neutralize oxidative stress. 
 
 A scheme for oxidative stress  
 
The balance between endogenous free radicals and antioxidants determines the redox 
status in biological systems (Figure 1-1). In normal conditions where the balance is well 
kept, minimal oxidative stress related damage is caused; while in disease conditions 
where the balance is tipped towards free radicals, increased oxidative stress related 
damage is observed which could further lead to disease progression. Normally the 
biological system can balance the production of free radicals and levels of endogenous 
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antioxidants to maintain redox equilibrium. However, under disease conditions when the 
biological system is unable to adjust the production of free radicals and endogenous 
antioxidants appropriately, oxidative stress can be caused by either increased free radicals 
or decreased endogenous antioxidants.  
 
 
 
Figure 1-1 Oxidative stress is caused by either increased free radicals or decreased 
antioxidants (adapted from (Scandalios, 2005)). 
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Damage caused by oxidative stress and related biomarkers 
 
Oxidative stress could damage macromolecules and cause detrimental effects on the cells. 
Free radicals can lead to elevated lipid peroxidation, DNA oxidation and protein nitration 
(Shukla et al., 2011a). Accordingly, several biomarkers for evaluation of oxidative stress 
were reported and validated in vitro and in vivo, including lipid peroxidation biomarkers 
of 4-hydroxynonenal and malondialdehyde, protein oxidation and nitration biomarkers of 
protein carbonyl groups and 3-nitrotyrosine, carbohydrates oxidation biomarkers of 
advanced glycation end products (AGE) and Receptor for AGE (RAGE), DNA/RNA 
oxidation biomarkers of 8-hydroxyguanosine and 8-hydroxy-2'deoxyguanosine (Sultana 
et al., 2013), depletion of GSH levels indicating decreased endogenous antioxidants 
(Petrillo et al., 2013b). These biomarkers and more others under investigation are useful 
to monitor oxidative stress and evaluate drug efficacy in neurodegenerative disease. 
 
In addition, oxidative stress is closely related to programmed cell death, which is referred 
to as “apoptosis”. Apoptosis is a main reason for the neuronal cell death in 
neurodegenerative disorders, the intrinsic pathway of which is also closely related to 
oxidative stress. Elevated oxidative stress activates the mitochondrial permeability 
transition pore (mtPTP) and results in collapse of mitochondrial inner membrane 
potential and mitochondrial dysfunction. ATP production is reduced and apoptogenic 
mitochondrial mediators are released including “cytochrome c, procapases 2, 3, and 9, 
apoptosis-initiating factor, and caspase activated DNase” etc. (Emerit et al., 2004). The 
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cell subsequently undergoes apoptosis pathway. Mitochondria induced apoptosis, or the 
intrinsic pathway as opposed to extrinsic pathways (Elmore, 2007), accounts for the most 
common cause of cell death in neurodegenerative disorders.  
 
The brain is more highly metabolic active but with much less cell regeneration, compared 
to other organs. Therefore brain is believed to be more sensitive to oxidative stress 
(Andersen, 2004). In addition, oxidative stress biomarkers were reported to increase 
within the same region of brain undergoing selective neurodegeneration. For example, 
lipid oxidation biomarkers have been reported to increase in the cortex and hippocampus 
of Alzheimer’s patients and the substantia nigra of Parkinson’s patients, co-localizing 
with neurodegenerative regions (Dexter et al., 1989, Butterfield et al., 2002). 
Dysregulation of GSH homeostasis in brain is also reported in a number of 
neurodegenerative diseases including multiple sclerosis (Choi et al., 2011a), Parkinson’s 
disease (Sian et al., 1994), Alzheimer’s disease (Lovell et al., 1998), Huntington's 
disease, amyotrophic lateral sclerosis, and Friedreich's ataxia (Johnson et al., 2012). 
Interestingly, 40% reduction in GSH levels were found in substantia nigra region of 
brains from Parkinson’s patients compared to age-matched controls (Sian et al., 1994). In 
particular, the depletion of GSH was found to parallel the severity of Parkinson’s disease 
(Riederer et al., 1989). Results from these studies showed that oxidative stress paralleled 
the progression of neurodegeneration. Co-localization of oxidative stress markers and 
neuronal cell death might also indicate the cause and effect relationship between 
oxidative stress and neuronal cell death.  
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Cause and effect relationship between oxidative stress and neurodegeneration 
 
Despite evidence of close relationships between oxidative stress and neurodegeneration, 
whether oxidative stress is the cause or consequence of neurodegeneration is still under 
investigation. Also, the relationship between oxidative stress and other pathologic process 
such as inflammation is unclear. These unanswered questions are the key to decipher the 
mechanism of neuronal cell death and neurodegeneration. A wide range of studies in 
recent literatures focused on investigation of the close relationship between oxidative 
stress and neurodegeneration. E.g., oxidative stress biomarkers were reported to be one of 
the earliest detectable biochemical changes in Parkinson’s patients, even earlier than 
markers for dopamine loss or dopaminergic neurodegeneration (Riederer et al., 1989). 
Chinta et al. showed that depletion of GSH within the substantia nigra region resulted in 
nigrostriatal neurodegeneration in mice, providing in-vivo evidence of a causal 
relationship between oxidative stress and Parkinson’s disease (Chinta et al., 2007). Based 
on these proofs, Singh et al. proposed a three-hit hypothesis for ALD, assuming oxidative 
stress as the first hit which causes subsequent inflammation, leading to loss of cell 
function and cell death as well as disease progression (Singh and Pujol, 2010). Similarly, 
Zhu et al. proposed a two-hit hypothesis where oxidative stress plays an important role in 
the early progression of Alzheimer’s disease (Zhu et al., 2007). An improved 
understanding of the relationship between oxidative stress and neurodegenerative 
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disorder may provide possible efficient therapies towards the treatment of other types of 
neurodegenerative disorders.  
 
1.1.3 Antioxidant therapy in neurodegenerative diseases 
 
Recently it was found that endogenous antioxidants were depleted under conditions of 
neurodegeneration and that oxidative stress contributes to the progression of 
neurodegeneration (Fourcade et al., 2008, Matsuzawa et al., 2008). Supplementing 
exogenous antioxidants seems to be a reasonable therapy to mitigate oxidative stress and 
improve the redox status. Antioxidant therapy in neurodegeneration is being vigorously 
investigated, including antioxidants of superoxide dismutase, NAC, GSH, α-tocopherol 
and Coenzyme Q10 (Table 1-1).  
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Study  Drug tested Subjects studied  Results 
(Wengenack 
et al., 1997) 
Superoxide 
dismutase 
Rat with global 
cerebral ischemia and 
neurodegeneration 
Decreased 
hippocampal 
CA1 neuron loss 
(Holmay et 
al., 2013) 
N-acetylcysteine Parkinson’s, Gaucher’s 
patients and healthy 
volunteers 
Increased brain 
GSH levels 
(Adair et al., 
2001) 
N-acetylcysteine Probable Alzheimer's 
patients clinical trial 
No significant 
changes on most 
cognitive 
evaluations but a 
trend for NAC 
superiority is 
observed  
(Sechi et al., 
1996) 
Glutathione                                          Parkinson’s patients 
clinical trial 
Improvement in 
neurological 
symptoms 
(Sano et al., 
1997) 
α-tocopherol Alzheimer's patients 
clinical trial 
α-tocopherol and 
selegiline 
synergistically 
improve 
neurological 
symptoms 
(Parkinson-
study-
group, 
1993) 
α-tocopherol Parkinson’s patients 
clinical trial 
 
Ineffective in 
preventing the 
progression of 
disease in early 
stage 
(Shults et 
al., 1998) 
Coenzyme Q10 Parkinson’s patients 
clinical trial 
CoQ10 did not 
change the 
disease rating 
scale but 
improve complex 
I activity 
 
Table 1-1 Selected studies of antioxidant therapy in neurodegeneration 
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Exogenous antioxidants as therapy for neurodegeneration can be classified into two 
major groups, enzymatic and non-enzymatic molecules. Enzymatic molecules include 
superoxide dismutase, catalase and glutathione peroxidase and their mimetics etc. Non-
enzymatic antioxidants include direct free radical scavenging molecules such as 
tocopherols, GSH, and indirect acting molecules that reduce cellular metal 
concentrations, increase endogenous antioxidants and target to relieve metabolic burden 
on cellular organelles, e.g., mitochondria such as ion chelators, NAC and Coenzyme Q10.  
 
In one open label study in early-stage, asymptomatic Parkinson’s patients, 600mg twice 
daily GSH was administered intravenously in 9 patients for 30 days. Results indicated 
that patients improved significantly after treatment compared to baseline and washout 
periods (Sechi et al., 1996). However, the idea of direct GSH dosing requires careful 
examination since whether reduced GSH can be transported across the BBB is still 
controversial and under investigation (Cornford et al., 1978, Kannan et al., 1990, Kannan 
et al., 2000). According to these reports, very limited GSH is transported across the BBB.  
 
In addition, other antioxidants are also widely investigated in neurodegenerative diseases. 
α-tocopherol (Vitamin E) was shown to be as good as selegiline in a large scale 
controlled trial to slow the progression of Alzheimer's disease. In addition, a treatment 
group with both α-tocopherol and selegiline showed synergistic effects (Sano et al., 
1997). However, in one large-scale randomized control trial, tocopherol was shown to be 
ineffective in preventing the progression in early Parkinson’s patients (Parkinson-study-
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group, 1993). Despite several successful clinical trials and encouraging cell and animal 
studies, antioxidant therapy was shown to have varying degree of success (Table 1-1). 
The inconclusive results suggest a better understanding of the roles for antioxidants in 
neurodegenerative disorders is required. And rationale dosing regimens and study designs 
are also crucial elements of a successful clinical trial.  
 
1.2 Adrenoleukodystrophy 
 
1.2.1 Definition, cause, clinical manifestation, pathology and current treatment 
options 
 
ALD is an X-linked genetic disorder which affects the adrenal glands, peripheral 
neuronal system, the spinal cord and white matter of the CNS. It is a progressive 
neurology disorder with incidence of 1 in 17,000 newborns. ALD has been shown to be 
caused by mutations in the ABCD1 gene, which encodes a member of the ATP binding 
cassette transporter protein family, and believed to function as a peroxisomal membrane 
transporter of very long chain fatty acid (VLCFA) (Kemp et al., 2012). Degradation of 
VLCFAs requires them to be transported into peroxisomes to facilitate β-oxidation. 
Mutations in ABCD1 transporter impair regular degradation of VLCFAs and cause 
intracellular accumulation (Figure 1-2). Igarashi et al. reported observation of increased 
levels of VLCFAs such as hexacosanoic acid (C:26:0) in the brain and adrenal tissues of 
ALD patients (Igarashi et al., 1976).  
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Figure 1-2 Mutations in ABCD1 gene cause adrenoleukodystrophy. Mutations in ABCD1 
gene cause dysfunctional adrenoleukodystrophy protein (ALDP), and impair the 
transport of VLCFAs into peroxisomes which consequently prevents the degradation of 
VLCFAs. As a result, intracellular VLCFAs accumulate and cause detrimental effects. 
VLCFAs mainly come from the elongation reactions which take place at the endoplasmic 
reticulum, catalyzing the elongation of very long-chain fatty acids enzymes (ELOVL). 
(Figure adapted from: (Engelen et al., 2008)) 
 
1.2.2 Diagnosis, clinical phenotypes and disease progression stages 
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ALD is an X-linked genetic disorder which affects males, while females may be carriers 
of the mutated gene. ALD has several different clinical phenotypes. The two major forms 
are childhood cerebral ALD (CCALD), usually affecting boys 4-10 years of age, and 
adrenomyeloneuropathy (AMN) typically affecting patients in early adulthood. 
Approximately 35-40% of the total patient population develops CCALD, which is the 
most severe phenotype. CCALD is characterized by impairment of CNS, generally 
rapidly progressive development and primarily affecting pediatric patient population. 
Death typically occurs within 2-4 years of symptoms onset in CCALD without 
interventions (Berger et al., 2013). 
 
Diagnostic tools for general ALD include genetic and biochemistry assays. ABCD1 gene 
mutation analysis is useful in ALD diagnosis. However, more than 1400 different 
mutations have been identified in ABCD1 so far (Kemp et al., 2001) and almost 50% of 
all mutations are non-recurrent, meaning they are specific to certain individual patient. 
And no clear correlations between a specific genetic mutation and clinical 
phenotypes/disease stages have been discovered. The characteristic biochemistry assay 
for ALD is the measurement of VLCFAs levels. VCLFAs levels are represented by 
C26:0 concentration, the ratio of C24:0/C22:0, and the ratio of C26:0/C22:0 in plasma, 
all of which are highly specific and sensitive. 99.9% of ALD patients were found to have 
elevated VLCFAs compared to control group (Valianpour et al., 2003). This test can also 
identify female carriers whose levels typically fall between control and ALD males. 
Interestingly, plasma levels of VLCFAs do not correlate with forms of disease or stages 
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of disease progression (Ofman et al., 2010) while concentrations of VLCFAs in white 
matter of brain tissues (myelin sheath) correlate with severity of ALD phenotypes 
(Asheuer et al., 2005).  
 
Diagnosis and disease monitoring are quite important in the treatment of ALD, especially 
for the most severe form CCALD, in order to implement effective treatments.  Often it is 
quite difficult to diagnose CCALD in the early stage, except those with known genetic 
family history. Patients are usually asymptomatic before 4 years old, and presentation of 
mild behavior symptoms occurs around 4 to 8 years old, usually followed by aggressively 
rapid CNS dysfunction, total disability and death within 2 years of time. Those early 
symptoms of learning and behavioral deficits are often mistaken as attention deficit 
disorder or hyperactivity until ALD specialists get involved. The diagnosis of CCALD 
usually takes long time. And patients may already come to the late stage. 
 
Brain Magnetic Resonance Imaging (MRI) provides the first diagnostic lead in detecting 
the cerebral neurological symptoms in CCALD patients. MRI patterns in CCALD 
patients could facilitate the prediction of disease progression or selection of treatment 
strategies (Loes et al., 2003).  The Loes score (0-34), a point rating system developed 
based on MRI severity, was established to help better define the ALD disease in 
conjunction with other clinical parameters (Loes et al., 1994). Males with ALD were 
suggested to undergo MRI every 6 months during childhood and yearly for adulthood to 
watch for cerebral manifestation. (Peters et al., 2004) 
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1.2.3 The role of oxidative stress in ALD 
 
Although the pathology of ALD is only partially understood, accumulation of 
intracellular VLCFA, along with other environmental factors such as oxidative stress and 
inflammation, is thought to trigger subsequent neuronal cell death, demyelination and 
neurodegeneration (Powers et al., 2005, Galea et al., 2012).  
 
Both an increase in free radicals and a decrease in endogenous antioxidants can lead to 
oxidative stress. Evidence of oxidative stress as a hallmark of ALD has been shown in 
recent studies. Vargas et al. evaluated oxidative stress biomarkers in plasma, erythrocytes 
and fibroblasts from ALD patients. Results showed that biomarkers of free radicals and 
lipid peroxidation were elevated in ALD patients compared to control, while total 
antioxidant capacity was decreased suggesting deficient capacity to rapidly handle 
oxidative stress (Vargas et al., 2004). Petrillo et al. observed decreased total and reduced 
GSH in lymphocytes of ALD patients as well as high levels of oxidized GSH forms 
(Petrillo et al., 2013b). Various clinical phenotypes of ALD including adult form of 
AMN, CCALD and heterogeneous female carriers were also examined in detail (Deon et 
al., 2007, Deon et al., 2008). In these studies, plasma levels of oxidative stress markers 
from both symptomatic and asymptomatic patients showed significant increase in lipid 
peroxidation, indicating oxidative stress as a hallmark for ALD disease. In addition, 
levels of total antioxidants were decreased in symptomatic patients while asymptomatic 
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patients stayed unchanged compared to control. From these studies, Deon et al. showed 
that the depletion of antioxidants exposed patients/carriers with ALD gene mutations 
with increased free radicals. However, asymptomatic patients/carriers do not present 
clinical symptoms with sufficient antioxidants while patients with depletion of 
antioxidants fail to defend against increased free radicals. 
 
Studies in ALD mouse models (Abcd1 knockout mice) provided another proof for the 
involvement of oxidative stress in pathogenesis of ALD. Increased ROS formation and 
elevation of other oxidative stress markers were observed in early phase of disease 
progression before manifestation of axonal degeneration in Abcd1 knockout mice 
(Fourcade et al., 2008). In addition, the same group showed that a combination of 
antioxidants containing α-tocopherol, NAC and α-lipoic acid reversed oxidative damage 
and axonal degeneration in Abcd1 knockout mice (Lopez-Erauskin et al., 2011a). Results 
indicated that oxidative stress was not only a hallmark of ALD but also the leading cause 
for disease progression.  
 
1.2.4 Treatment options and hematopoietic stem cell transplantation (HSCT)  
 
Treatment options for ALD are fairly limited. Adrenal steroid replacement therapy could 
account for the dysfunctional adrenal glands but has no effect on neurology system or 
disease progression (Moser, 2006). The use of Lorenzo’s oil as well as dietary restriction 
could efficiently lower the plasma levels of VLCFAs back to normal levels by week 10 
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of clinical trial (Aubourg et al., 1993). And Lorenzo’s oil was shown to reduce the risk to 
develop MRI abnormities which was correlated to reduced VLCFAs levels in 89 
asymptomatic patients (Moser et al., 2005b). However, no detectable clinical changes 
were observed in AMN patients following a mean interval of 33 months (Aubourg et al., 
1993). In addition, Lorenzo’s oil was found to have no effect on MRI progression in c- 
ALD with CNS manifestation (Duchesne et al., 1995). These inconsistent reported results 
might be due to the fact that most of them are single-armed studies without well-
controlled group. In addition, gene therapy was also investigated for ALD, with 
promising preliminary results in small group of patients (Cartier and Aubourg, 2010, 
Cartier et al., 2010, Biffi et al., 2011). 
 
Hematopoietic stem cell transplantation (HSCT) has been demonstrated to be the most 
successful therapy for CCALD, which was shown to halt disease progression in multiple 
clinical trials and displayed consistent efficacy during the early stage of ALD (Peters et 
al., 2004). However, survival rates for patients receiving HSCT highly depend on the 
neurologic clinical stages at the time of the procedure. 5-year survival for patients 
receiving HSCT during late stage CCALD, defined as MRI severity score (Loes score 
from MRI images) more than 9 and with more than one neurological deficit, was reported 
to be 45%, while the survival rate was 92% for early stage patients (Peters et al., 2004). 
The prognosis is poor for late-stage CCALD due to extensive demyelination in the brain 
white matters.  
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The low survival rate of performing HSCT in advanced CCALD patients prompted the 
Blood and Marrow Transplantation Group at University of Minnesota to add NAC 
adjuvant therapy to HSCT. Late-stage CCALD patients were given large doses of 
intravenous NAC infusion (70 mg/kg infusion over 1 hour every 6 hours), beginning after 
the administration of chemotherapy through 100 days post-transplantation. Significantly 
greater survival rate was observed in the NAC treatment group (84%) compared to 
untreated group (36%). Although historical controls were used in the comparison, the 
results were quite encouraging and suggesting the beneficial effects of antioxidants in 
HSCT for late-stage CCALD (Tolar et al., 2007, Miller et al., 2011). Although NAC 
adjuvant therapy appears to increase survival, the mechanism of action for NAC is not 
clear, and the rationale for NAC dosing (70mg/kg every 6 hours for over approximately 
100 days) is not clear either.  
 
Although HSCT procedures and NAC adjuvant therapy increase the survival rates in 
CCALD patients, the symptoms of neurodegeneration in CNS are not improved in these 
patients (Miller et al., 2011).  
 
1.3 N-acetylcysteine 
 
1.3.1 History and status, indications and therapeutic applications 
 
 
NAC is a thiol-containing antioxidant, available both as FDA-approved products and 
dietary supplements. NAC is indicated as an inhaled agent for mucolysis in cystic fibrosis 
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(Mucomyst®) and intravenously as an antidote for acetaminophen overdose 
(Acetadote®) (Heard and Green, 2012b, Rushworth and Megson, 2013a). Recently, NAC 
has gained renewed attention as a potential therapy for a number of conditions including 
pulmonary (Sadowska et al., 2006), neurological (Adair et al., 2001, Berman et al., 2011), 
psychiatric (Dean et al., 2011a), and cardiovascular (Marian et al., 2006, Mahmoud and 
Ammar, 2011), metabolic deficiency (Atkuri et al., 2007) disorders and diseases. 
Although NAC has a long history of clinical use, its biotransformation and distribution as 
well as mechanisms of action are not fully understood. 
  
1.3.2 Physical-chemical properties 
 
NAC is a derivative of the naturally occurring amino acid L-cysteine, with an acetyl 
group attached to its nitrogen atom. The chemical formula of NAC is C5H9NO3S, with a 
molecular weight of 163.2 g/mol. NAC is a white crystalline powder, with melting point 
around 104° ~110°C (Package insert for Acetadote, 2004). Its structure is shown in 
Figure 1-3. 
 
 
Figure 1-3 Chemical structure of NAC 
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Acetadote
®
, the sterile NAC solution, contains 20% w/v (200 mg/mL) NAC. The pH of 
the solution is around 6.0~7.5. This condensed solution is diluted in compatible diluents 
before use. It also has a slight unpleasant odor. 
 
1.3.3 Pharmacokinetics 
       
Absorption and disposition 
 
 
The bioavailability of oral NAC is reported to be low (~4-10%) in healthy adults 
(Borgstrom et al., 1986, Olsson et al., 1988). Interestingly, a meta-analysis found little 
difference in outcomes between oral and intravenous formulation of NAC in treating 
acetaminophen overdose (Buckley et al., 1999). This is probably because NAC or its 
metabolite cysteine during the first-pass metabolism can both be converted to GSH.  
Volume of distribution at steady state in healthy volunteers was reported as 0.47 L/Kg. 
The protein binding for NAC was reported to be 83% (Package insert for Acetadote, 
2004). The distribution of oral NAC into peripheral tissues such as liver, kidney, skin, 
thymus, spleen, eye, and serum is fairly quick and within 1 hour in rats (Arfsten et al., 
2007). Clinical pharmacokinetic information of NAC transportation into the Blood-Brain-
Barrier (BBB) or placenta is not adequate, although there is evidence of NAC crossing 
the BBB in animal studies (Neuwelt et al., 2001, Farr et al., 2003). The transportation of 
NAC across BBB requires more investigation. Moreover, NAC was found to increasingly 
enter into the brain following inflammation in the brain induced by LPS (Erickson et al., 
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2012). In addition, placental transfer of NAC in 4 pregnant women following treatment 
of acetaminophen overdose was also observed (Horowitz et al., 1997).  
 
Metabolism and biotransformation 
 
 
NAC forms cysteine, disulfides and conjugates with other thiols in vivo. Reported forms 
include N, N'-diacetylcysteine, N-acetylcysteine-cysteine, N-acetylcysteine-glutathione, 
N-acetylcysteine-protein etc. (Package insert for Acetadote, 2004).  
 
NAC, cysteine, and GSH are present in vivo in both the reduced (active) and oxidized 
(inactive) forms. The fate of NAC in the body follows several different pathways. The 
first one is the formation of cysteine via acyclase enzyme directly (Dringen and 
Hamprecht, 1999). Once deacetylated, cysteine, the rate-limiting substrate is available for 
cellular GSH synthesis. GSH may then be actively transported out of the cell where it is 
metabolized by a transpeptidase in extracellular fluid. However, cysteine is rapidly 
oxidized in plasma and extracellular fluid to cystine (oxidized form of cysteine) among 
other disulfide compounds. There are also other pathways that NAC exchanges thiol with 
cystine and releases free reduced form cysteine for GSH synthesis, or that NAC directly 
exchanges thiol with oxidized form of GSH and releases reduced GSH. 
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Figure 1-4 Biotransformation of NAC. The formation of cysteine, GSH and H2S from 
NAC and transportation into cells are shown. (Figure adapted with the permission of 
Coles L.) 
 
NAC is also a plausible precursor for hydrogen sulfide (H2S) (Kartha et al., 2012). The 
two enzymes Cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) are 
responsible for H2S synthesis from cysteine. H2S is a gasotransmitter similar to Nitric 
oxide (NO) and Carbon monoxide (CO). Recently, H2S has been widely studied in 
various disease conditions and has been found to elicit neuroprotective signaling 
pathways (Hu et al., 2011). H2S is further metabolized to thiosulfate which is more stable 
and easier to detect (Hildebrandt and Grieshaber, 2008). 
 
Elimination 
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Published NAC pharmacokinetic studies report widely varied results which appear 
dependent on the method of analysis (Olsson et al., 1988). Borgstromet al. reported an 
elimination half-life of 2.27 h after IV administration in healthy adult volunteers, whereas 
others have observed a mean half-life of approximately 6 h (Borgstrom et al., 1986, 
Holdiness, 1991). The elimination rate of NAC in pediatric population is possibly 
different from adults. A study in pre-term newborn infants reported a mean elimination 
half-life of 11 h following IV administration (Ahola et al., 1999). Renal clearance is 
reported to be approximately 30% of the total Clearance (Package insert for Acetadote, 
2004).  
 
1.3.4 Pharmacology 
 
NAC is a thiol-containing compound that increases the biosynthesis of GSH, a potent 
endogenous antioxidant. GSH is a crucial antioxidant in cells that protects against 
damage from free radicals (Wu et al., 2004a). In addition, mitochondrial GSH is 
receiving more and more attention due to its influence in oxidative stress related 
pathological conditions. Mitochondrial GSH has emerged as the major defense 
mechanism to maintain mitochondrial function (Mari et al., 2009).  
 
In addition, NAC has other pharmacological properties that play key roles in mitigating 
oxidative stress and inflammation. These include acting as direct free radical scavengers, 
regulators of tissue protective genes and proteins, as well as chelator and anti-
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inflammatory agent, methyl donor in the conversion of homocysteine to methionine, 
glutamate transport facilitator, and protein modifier (Zafarullah et al., 2003, Dodd et al., 
2008). In particular, NAC regulates tissue protective genes that reduce damage inflicted 
by reactive oxygen species (ROS). One example of a cytoprotective protein that is 
inducible by thiol-containing biomolecules is hemeoxygenase-1 (HO-1). This enzyme 
catalyzes the oxidative metabolism of heme to form equimolar amounts of biliverdin, 
carbon monoxide (CO) and free iron, all of which have antioxidative effects (Abraham 
and Kappas, 2008). HO-1 and its downstream products are considered to be mediators of 
cytoprotective effects that might be of particular significant defending system against 
oxidative stress. 
 
1.3.5 Side effects and adverse responses 
 
The severity of NAC side effects ranges from nausea to death. The most common side 
effect of NAC is the rotten egg odor related nausea.  And some of its adverse responses 
are referred to as “anaphylactoid”, which shares similar clinical manifestations as 
anaphylaxis, but does not involve IgE-mediated immunological responses. The patterns 
of side effects are quite different with oral and intravenous administration of NAC. 
Gastrointestinal effects such as nausea and vomiting are more common in oral 
administration and anaphylactoid reactions are more common in intravenous 
administration (Bebarta et al., 2010). 
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The frequency of anaphylactoid is reported in a wide range, as 2-6% (Bebarta et al., 
2010), 9.3% (Whyte et al., 2007), 14.9% (Waring et al., 2008) and 48% (Lynch and 
Robertson, 2004) in patients with acetaminophen overdose. The most frequent reported 
side effects are cutaneous anaphylactoid reactions include rash, urticaria, pruritus and 
angioedema (Sandilands and Bateman, 2009) and other adverse responses include 
bronchospasm and hypotension. In extreme cases, cardiac arrest was reported (Cassidy et 
al., 2008) as well as fatal anaphylactoid reaction in a patient with asthma (Appelboam et 
al., 2002).  Despite these potential concerns, the toxicity observed with intravenous NAC 
in the ALD population has proven to be minimal.   
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CHAPTER 2 
RESEARCH RATIONALE, SCOPE 
AND GENERAL APPROACHES 
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2.1 Hypothesis and specific aims 
 
Oxidative stress plays an important role in neurodegenerative disorders such as ALD and 
antioxidant therapy including NAC may be potential efficient therapy. The focus of my 
research is to characterize the role of oxidative stress in ALD, and investigate the 
pharmacology of NAC in in-vitro, in-vivo and clinical models. 
 
 
Figure 2-1 Hypothesis for research; increased ROS, mitochondrial dysfunction and 
subsequent cell death are caused by accumulation of VLCFAs in CCALD, and addition of 
NAC reverses the oxidative stress status and improves cell survival through 
supplementing mitochondrial GSH and induction of HO-1.  
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The hypothesis is that increased ROS is caused by accumulation of VLCFAs which 
further leads to mitochondrial dysfunction and cell death, and NAC reduces oxidative 
stress and improves cell survival through generation of antioxidants (e.g., GSH), 
regulation of cytoprotective proteins (e.g., HO-1) and restoration of mitochondrial 
function (Figure 2-1).  
 
Based on this hypothesis, four specific aims were formed and pursued in four projects:  
Specific Aim 1: To characterize the expression of antioxidant proteins (HO-1, ferritin) 
following NAC exposure in CCALD patients; 
Specific Aim 2: To investigate the cytoprotective role of NAC in vitro;   
Specific Aim 3: To determine the PK/PD relationship following NAC exposure in vivo; 
Specific Aim 4: To examine the effects of NAC on mitochondrial function in vitro. 
 
2.2 General approaches for research 
 
2.2.1 Disease-related pharmacological models 
 
Disease-related pharmacological models could greatly facilitate the validation of 
hypothesis and test of potential therapies. In order to investigate the pathology of ALD 
and the potential mechanisms of action of NAC, different in-vitro, in-vivo and clinical 
models were used in my research.  
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In-vitro models 
 
It’s widely known that CCALD is characterized with abnormal concentrations of 
VLCFAs which accumulate in the brain white matter and cause neurodegeneration. 
Oligodendrocyte is the major cell type in the white matter of brain, thus oligodendrocyte 
cells challenged with similar concentrations of VLCFAs as in patients are established as 
the in-vitro model for ALD. Oxidative stress is also considered as a crucial component in 
ALD disease pathology. Oligodendrocyte cells challenged with H2O2 are also used as an 
in-vitro cell model to mimic oxidative stress. Oligodendrocytes with genetic mutation and 
previous proof of endogenous oxidative stress are also explored. Meanwhile, fibroblast 
cells derived from ALD patients are also considered as a valuable in-vitro model 
(Fourcade et al., 2008) and used for part of the proof-of-concept studies.  
 
In-vivo models 
 
Abcd1 knock-out mice are used widely as an effective tool for ALD research (Lopez-
Erauskin et al., 2011a). By generating null mutations on the Abcd1 gene, mouse displays 
similar impaired VLCFAs degradation in peroxisomes and accumulation of VLCFAs in 
the plasma and tissues. However, this mouse model has been widely criticized for the 
absence of cerebral neurodegeneration symptoms. No obvious myelin pathology is 
observed in the brain tissues of Abcd1 knock-out mouse model. And it turns out Abcd1 
mutations and VLCFAs accumulations are not enough to cause neurodegeneration in 
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mouse. Interestingly, although without presentation of brain and spinal cord 
neurodegeneration similar to CCALD, Abcd1 knock-out mice present peripheral 
neuropathy symptoms similar to the adult form AMN.  
 
In recognizing the defects of Abcd1 knock-out mice in the research of CCALD, pex5 
gene, an essential peroxisome biogenesis factor, is selectively inactivated in 
oligodendrocytes in Pex5 knock-out mice. This mutation leads to widespread axonal 
degeneration and cerebral demyelination, similar to clinical symptoms in CCALD 
patients (Kassmann et al., 2007). The fact that oligodendrocyte-specific peroxisomal 
dysfunction leads to cerebral symptoms, indicates that oligodendrocytes play an 
important role in preventing axon degeneration and demyelination. 
 
At this initial stage of research, wild-type mice were used to obtain preliminary PK/PD 
data in preparation for further studies in Abcd1 knock-out mice or Pex5 knock-out mice.  
 
Clinical samples 
CCALD is one major subtype among ALD patients. The Bone Marrow Transplantation 
(BMT) Group located at University of Minnesota is one of the major centers performing 
transplants for patients with CCALD (Miller et al., 2011). In collaboration with the BMT 
group, plasma samples from CCALD patients were collected and used for antioxidant 
protein identification and measurement. 
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2.2.2 Pharmacokinetic-pharmacodynamic modeling 
 
Pharmacokinetics (PK) refers to the study of time course of drug absorption, distribution, 
metabolism and excretion, describing changes in plasma concentrations of target 
molecules over time. Pharmacodynamics (PD) is defined as the study of time course of 
pharmacological responses elicited by target molecules (Meibohm and Derendorf, 1997). 
For example, the study of tumor growth curve in patients after chemotherapies is 
considered as PD study while the study of drug concentrations used during chemotherapy 
is considered as PK study.  
 
The aim of PK/PD modeling is to establish the relationship between drug concentrations 
and drug effects following drug administration. Mathematical equations are used as 
efficient tools to describe and establish the PK/PD models. PK/PD modeling is useful 
tool at various stages of pre-clinical and clinical development, contributing to drug 
candidate selection and optimization, design of first-in-human study as well as clinical 
development (Lave et al., 2007). Successful PK/PD models help clinicians to adjust doses 
in clinical practice and facilitate new drug development. They are quite useful tools in:  
1) Description of drug exposure-response time profile;  
2) Understanding of  detailed drug mechanisms and/or making judgments among 
different hypothesis of  mechanisms of action; 
  36 
3) Prediction of drug expose-response under new dosing regimens, physiological 
conditions (e.g., disease conditions or during drug-drug interaction), or different 
experimental systems (e.g., in vitro-in vivo correlations). 
4) Identification and quantification of system variables which could play a role in 
PK/PD relationships (e.g. creatinine clearance, weight, age, sex etc.) 
5) Explanation of the observed variability of responses in patients’ population (e.g., 
separation of the total variability into between-subject variability and intra-individual 
variability). 
 
PK/PD models 
 
PK/PD models can be generally classified as empirical models, mechanism-based models 
and physiological models (Mager et al., 2003).  
1) Empirical models are solely based on the best-fit mathematical equations for 
PK/PD profile without considering the underlying mechanisms of action.  
2) Mechanism-based models incorporate the underlying drug mechanisms of 
action into the mathematical models which could be applied towards other drugs from 
the same category, e.g., receptor-occupancy models. 
3) Physiological models are established based on physiological information of 
biological systems. Blood flow rates are used to link between particular organs while 
partition ratios measured experimentally are used to define the properties of organs. 
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One type of models above or a combination of them is often used in PK/PD modeling and 
data analysis. In particular, mechanism-based models are widely used and applied 
towards different phases of drug development. Basic components of mechanism-based 
PD models for drug action are summarized as Figure 2-2 (Jusko et al., 1995, Mager et al., 
2003). 
 
 
Figure 2-2 Basic components of PD models of drug action. Cp is defined as the plasma 
concentration of drugs; Ce is defined as the concentration at the site of action, or 
referred as the effect compartment; Keo is the first-order rate constant that links the 
plasma concentration and the effect compartment concentration; H refers to the 
biosensor process which involves the direct interaction between the drug concentration 
at the site of action and the biological process; Kin and Kout are defined as rate of 
production and loss of the endogenous mediators within the biosignal flux; R(response) is 
the pharmacological effect, or the PD endpoint measured during the study. Figure 
adapted from (Jusko et al., 1995). 
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The PD endpoint (response) could be linked to the plasma concentration of the drug in 
various ways. Biophase distribution model describes the linkage between plasma 
concentration and the concentration at the site of action (effect compartment). Direct 
measurement of the effect compartment concentration is preferable but not realistic for 
most of studies. Biophase distribution model enables modeling of the delay in response 
due to the rate-limiting distribution. In addition, drugs could possibly elicit 
pharmacological effect indirectly through certain endogenous biological mediator 
(biological flux). Drugs could increase or decrease the levels of the endogenous mediator, 
through stimulating/ inhibiting the rate of synthesis, or inhibiting/stimulating the rate of 
clearance. Further, the endogenous mediators could elicit more biological responses 
through signal transduction which can be modeled quite differently depending on the 
mechanism of action. 
  
Population PK/PD modeling 
 
Population PK/PD modeling is to study PK/PD models in a population, where data from 
all individuals are evaluated simultaneously with a nonlinear mixed-effects model. The 
term “nonlinear” means that the dependent variables (e.g., drug concentration or drug 
effect in PK/PD) can be expressed with nonlinear functions of model parameters and 
independent variables (e.g., time). “Mixed-effects model” quantifies the influence of 
fixed-effect parameters and random-effect parameters simultaneously on the dependent 
variable. Fixed-effect parameters refer to the average population value or average 
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relationship with measurable patients’ factors (e.g., average population clearance, or 
weight that do not vary across individuals). Random-effect parameters describe the 
unexplained between-individual and within-individual random variability in a model, 
sometimes inter-occasional variability is also considered. This population method enables 
one to investigate the variability observed in PK and PD outcomes among individuals and 
within individuals at different occasions (Mould and Upton, 2013). 
 
The primary goal of population PK/PD is to find average population values and 
determine the sources of variability in a population. With enough information, one could 
possibly relate the drug concentration/drug effect with dosing regimens (e.g., dose, 
interval, route of administration) and patient characteristics (e.g., age, weight, renal 
clearance, ethic, genetic), predicting the outcomes of a new regimen or for another patient 
population.  
 
In population PK/PD modeling, structural model of nonlinear parameter function is 
established with PK model, PD model and disease progression model; statistical model 
describes the variability around the structural model, including the information of intra- 
and inter- individual variability; covariate model identifies the patients’ individual 
demographic factors which influence the parameters (e.g., Vi = V×EXP (BWi/70), Vi is 
individual volume of distribution, V is the population average, BWi is the individual 
body weight (Cella et al., 2012)). 
 
  40 
2.3 My roles in projects 
 
Four projects as well as my role in each project were listed below:   
 
Project 1:  Investigation of cytoprotective biomarker (HO-1) in NAC pharmacology in 
CCALD patients; 
• Authored abstract and poster (American Society for Clinical Pharmacology and 
Therapeutics Annual Meeting, Washington, 2012), presentations and manuscript; 
• Contributed in assay validation, standardized the detection methods, authored 
standard operation protocols; 
• Carried out all the experiments and data analysis. 
 
Project 2: Investigation of mechanisms of action of NAC in oxidative-stress cell models 
of oligodendrocytes;  
• Authored grant application, abstract and poster (Chemistry Biology Interface 
Training Grant Symposium, MN, 2011), presentations and manuscript; 
• Contributed in the study design, standardized the sampling/detection methods, 
authored standard operation protocols; 
• Carried out all the experiments and data analysis. 
 
Project 3: Investigation of the role of mitochondrial function in ALD pathology and 
mechanisms of action of NAC in VLCFAs challenged oligodendrocytes 
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• Authored grant application, abstract and poster (Mitochondrial Medicine 
symposium, CA, 2013), presentations and manuscript; 
• Collaborated and communicated between PIs from two different labs, 
contributed in the study design, purchased materials and standardized the 
sampling/detection methods, authored standard operation protocols; 
• Carried out all the experiments and data analysis. 
 
Project 4: Investigation of PK/PD properties of single i.v. dose of NAC in mice 
• Authored grant application (not funded though), presentations and manuscript; 
• Collaborated and communicated between PIs from three different labs, 
contributed in the study design, purchased materials and standardized the 
sampling/detection methods, managed the logistics of sample collection and analysis, 
authored standard operation protocols; 
• Carried out the quantification analysis of samples; 
• Performed non-compartmental and compartmental PK analysis and PK/PD 
modeling. 
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CHAPTER 3 
NAC THERAPY INCREASED PLASMA 
CONCENTRATIONS OF HEME OXYGENASE-1 IN 
CCALD PATIENTS 
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3.1 Introduction 
 
NAC is used as adjuvant therapy along with HSCT in late-stage CCALD, resulting in 
increased survival from 36% to 84% (Miller et al., 2011). These patients received high 
dose of NAC for a long period of time. However, the underlying mechanism is unknown. 
NAC is a thiol-containing antioxidant that scavenges free radicals, chelates metal ions, 
facilitates GSH biosynthesis (Zafarullah et al., 2003), contributes to the synthesis of 
gasotransmitter hydrogen sulfide (Kartha et al., 2012) as well as regulates tissue 
protective genes and proteins that reduce damage inflicted by reactive oxygen species 
(ROS) (Zafarullah et al., 2003).  
 
An example of cytoprotective proteins induced by thiol-containing biomolecules is 
hemeoxygenase-1 (HO-1). HO-1 is a 32-kDa microsomal protein which catalyzes the 
oxidation of heme to form biliverdin, carbon monoxide (CO) and free iron. Biliverdin is 
then reduced by biliverdin reductase (BVR), forming a potent free radical scavenger and 
antioxidant biliverdin (Tenhunen et al., 1968). CO has been shown to provide 
neuroprotective effects through the soluble guanylate-cyclase (sGC) pathway, and also 
have anti-apoptotic, and anti-inflammatory actions (Brouard et al., 2000, Otterbein et al., 
2000, Schallner et al., 2013). The HO-1-dependent release of free irons during heme 
oxidation results in the upregulation of a secondary protein, ferritin (Eisenstein et al., 
1991). Ferritin functions as an endogenous antioxidative protein by rapidly sequestering 
free cytosolic irons, which catalyzes oxygen centered radical formation via the Fenton 
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reaction in cells (Juckett et al., 1995). In total, HO-1 and its downstream products are 
considered to be the 2
nd
 most important in antioxidant defense system after GSH (Dulak 
and Jozkowicz, 2003). Their cytoprotective effects may be particular significant during 
conditions of oxidative stress given there are excessive free radicals and depleted 
antioxidants.  
 
HO-1 is expressed extensively at low basal levels in normal tissues apart from liver and 
spleen (Tenhunen et al., 1968). However, HO-1 can be upregulated by a variety of pro-
oxidant and stress stimuli as a sensitive oxidative stress marker. Increased HO-1 
concentrations are generally considered as a signal of the biological system to restore 
redox homeostasis (Cuadrado and Rojo, 2008). Thus modulation of HO-1 expressions 
within the therapeutic range is critical to oxidative stress related disorders (Jazwa and 
Cuadrado, 2010).  
 
Cysteine, GSH and H2S, the three major metabolites of NAC (Zafarullah et al., 2003, 
Kartha et al., 2012), have been shown to induce HO-1 expression in vitro (Erdman, K., 
unpublished data from our lab). We reasonably hypothesized that the concentrations of 
HO-1 are increased in CCALD patients with exposure of NAC and its metabolites. To 
test this hypothesis, plasma HO-1 concentrations were measured since it was identified as 
a useful surrogate biomarker for HO-1 expression in vivo (Bao et al., 2010, Bao et al., 
2012, Zager et al., 2012). In the current study, plasma concentrations of HO-1 and its 
downstream ferritin were measured in CCALD patients prior to and after NAC dosing.  
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As part of the HSCT procedure, CCALD patients received extensive preparatory regimen 
(Figure 3-1). The HSCT procedure and chemotherapy used could also possibly affect 
HO-1 and ferritin concentrations. In fact plasma ferritin levels were found to be increased 
considerably during the first 3 months following HSCT (Or et al., 1987). Total body 
irradiation (Suzuki et al., 2002), mycophenylate mofetil (MMF) and cyclosporine (CSA) 
(Teng et al., 2006) were also found to induce HO-1 levels in vivo. In contrast, 
Clofarabine was found to decrease HO-1 expression (Lee et al., 2012). No previous 
reports have addressed the influence of campath-1H and Melphalan on HO-1 expression. 
In this study, we also explored plasma HO-1 and ferritin levels following HSCT 
procedure. 
 
3.2 Methods 
 
3.2.1 Demographics of patients, NAC dosing and blood sampling 
 
17 CCALD patients scheduled to undergo HSCT at the University of Minnesota Blood 
and Marrow Transplant (BMT) Program were included in this study. In accordance with 
the Declaration of Helsinki and following the provision of informed consent by patients 
or guardians, protocols were approved by the University of Minnesota Institutional 
Review Board. The inclusion/exclusion criteria require that patients were diagnosed with 
advanced radiographic disease (Loes score ≥ 10) and received the NAC adjuvant therapy 
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(70 mg/kg intravenously every 6 hours from -11 day till -8 day prior to HSCT, and day 1 
till day 100 post-HSCT procedures) as part of the protocol.  The HSCT regimen also 
includes campath-1H, clofarabine, melphalan, total body irradiation (TBI), 
mycophenylate mofetil (MMF) and cyclosporine (CSA) as shown in Figure 3-1.  
 
Plasma samples were drawn from patients prior to NAC therapy (-12day, PRE-NAC) and 
post NAC therapy (-8 days, POST-NAC-1; +7 days, POST-NAC-2; +21days, POST-
NAC-3) as shown in Figure 3-1. Few sampling points were not obtainable in some of the 
patients. We obtained PRE-NAC and POST-NAC1 samples from 11 patients. Data from 
these 11 patients were taken for further analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSCT 
Infusion 
Campath  1H 
0.3 mg/kg x 5 days 
0 -1 -2 
Clofarabine 
40 mg/m 2  x 5 days 
-3 
TBI 
-4 -5 -6 -7 -8 -9 -10 -11 -12 
Melphalan 
140 mg/m 
MMF to Day 30 
CSA to Day 100 
NAC (mucomyst) 70mg/kg per 6hrs  
-11 day to -8 day; and day 1 to day 100 
+7 +21 
PRE-NAC 
(-12 day) 
POST-NAC-1 
(-8 day) 
POST-NAC-2 
(+7 day) 
POST-NAC-3 
(+21 day) 
 
Figure 3-1 HSCT procedures with NAC adjuvant therapy for CCALD patients. In 
addition to preparative drugs used in the protocol, NAC was administered intravenously 
at 70 mg/kg every 6 hours from -11 day till -8 day prior to HSCT, and day 1 till day 100 
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post-HSCT. Plasma samples were drawn at 4 time points including -12 day (PRE-NAC), 
-8 day (POST-NAC-1),  +7 day (POST-NAC-2) and +21days (POST-NAC-3).  
 
3.2.2 Determination of plasma HO-1 concentrations 
 
Plasma HO-1 levels were determined using commercial HO-1 ELISA kit (Enzo Life 
Sciences, MI, USA). Briefly, plasma samples were first centrifuged at 13000 rpm for 
10mins, and diluted subsequently with rat HO-1 diluents (Enzo Life Sciences, MI, USA) 
at a ratio of 1:2. The subsequent assay procedures were performed as per the 
manufacture’s protocol. Normal human plasma (Biological Specialty Corporation, PA, 
USA) and normal human plasma spiked with 10ng/ml HO-1 standard (Enzo Life 
Sciences, MI, USA) were used as control samples. The two control samples were run in 
parallel with each set of test samples. After the assay, the data was analyzed using a  4-
parameter algorithm to calculate the plasma HO-1 concentrations. 
 
3.2.3 Determination of plasma ferritin concentrations 
 
Plasma ferritin concentrations were determined using commercial ferritin ELISA kit 
(Abnova, Taiwan). Plasma samples were first centrifuged at 13000 rpm for 10mins, and 
diluted using diluent provided by the kit. PRE-NAC and POST-NAC-1 samples were 
diluted at ratio of 1:2 while POST-NAC-2 and POST-NAC-3 samples were diluted at 
ratio of 1:20. The subsequent assay procedures were performed as per the manufacture’s 
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protocol. Normal human plasma (Biological Specialty Corporation, PA,USA) and normal 
human plasma spiked with 50ng/ml and 250ng/ml ferritin were taken as control samples. 
The three control samples were run in parallel with each set of test samples. After the 
assay, the data was analyzed using 4-parameter algorithm to calculate the plasma ferritin 
concentrations. 
 
3.2.4 In-vitro cell culture  
 
Around 10
4 
primary human non-transformed fibroblast cells (derived from non-CCALD 
human controls) were seeded on 24-well plates (Corning, NY, USA) in DMEM glucose 
media supplemented with 10% FBS and 1% antibiotics. Cells were incubated overnight 
in 37 °C incubator with 5% CO2. For experimental set up, cells were cultured overnight 
to get 80% confluence before being exposed to NAC (10µM-100µM) for 4 hours. HO-1 
mRNA expression was quantified using real-time PCR (SYBR green method) and protein 
expression by ELISA.  
 
3.2.5 Real time PCR  
 
Real time PCR  
Approximately 105 primary human fibroblast cells were trypsinized and harvested from 
24-well plate. Cell pellets were collected and stored at -80 °C freezer. Total RNA was 
extracted from frozen pellets using RNeasy Plus Mini kit (Qiagen, CA, USA) according 
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to the manufacture’s protocol. Quality of total RNA was assessed using non-denaturing 
agarose gel (1% agarose) electrophoresis to examine RNA degradation. Further, the 
concentration of total RNA was quantified using Take3™ plate (BioTek, VT,USA) and 
Synergy 2 spectrophotometer (BioTek, VT,USA), the readings of which provided quick 
spectrophotometric quantification of total RNA. Approximately 1μg of total RNA was 
used for reverse transcription using qScript cDNA synthesis kit (Quanta, MD, USA) in 
Mastercycler (Eppendorf, Germany). cDNA was amplified using SYBR green method 
(Clontech, CA, USA) following manufacturer’s protocol in MyiQ single color real-time 
PCR detection system (Bio-Rad, CA, USA). Real-time PCR results were analyzed by 
IQ5 optical system software (version 2.0, Bio-Rad) provided with the MyiQ system. 
Hypoxanthine phosphoribosyl transferase 1 gene (HPRT) was used as the normalization 
control for each sample.  
 
Primers for HO-1: FP, 5’-ATT GCC AGT GCC ACC AAG TTC AAG-3’; RP, 5’-ACG 
CAG TCT TGG CCT CTT CTA TCA-3’; Primers for HPRT: FP, 5’-GGT GAA AAG 
GAC CCC ACG AA- 3’; RP, 5’- AGT CAA GGG CAT ATC CTA CA-3’. 
 
3.2.6 Determination of HO-1 concentrations in cell lysates 
 
To quantify the HO-1 protein concentrations in vitro, cell lysates were harvested on 24-
well plates treated with different concentrations of NAC. HO-1 concentrations in cell 
lysate were analyzed using HO-1 ELISA kit (Enzo Life Sciences, MI, USA). Total 
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protein concentrations were analyzed by Bradford protein assay (Bio-RAD, CA) 
according to manufacturer’s protocol and used as normalization parameter across 
treatments.  
 
3.2.7 Statistical Analysis 
 
Results are expressed as means ± standard error. For multiple comparisons, one-way 
ANOVA and Dunnett's test were used. In addition, t-test was used to compare between 
two groups. The statistical methods are specified in each section of the results. A p-value 
<0.05 was considered significant. 
 
3.3 Results 
 
3.3.1 Demographics of CCALD patients  
Demographic and clinical characteristics of the study subjects are summarized as below. 
All patients were diagnosed with advanced radiographic disease (Loes score ≥ 10) at the 
time of enrollment. All 17 CCALD patients enrolled were male and the median age of 
ALD patients at the time of HSCT was 8.2 years old (range from 4.4 to 14.5 years). The 
median weight of ALD patients at the time of HSCT was 24.4 kg (range from 17.3kg to 
41.5 kg). The intravenous dose for NAC was 70mg/kg/6hrs for all patients. 
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3.3.2 NAC increases plasma concentrations of HO-1 and ferritin in CCALD 
patients prior to HSCT 
 
11 patients with samples prior to NAC therapy (-12 day, PRE-NAC) and post NAC but 
before HSCT (-8 day, POST-NAC-1) were taken for analysis. In these patients, NAC was 
dosed during the pre-conditioning period for 4 days (-11 day till -8 day). Analysis of 
plasma samples from CCALD patients prior to and 4 days after treatment with NAC 
showed significant increases in the antioxidant protein, HO-1 (Figure 3-2 A). We also 
observed significant increase in the concentrations of ferritin, a downstream product of 
HO-1 activity (Figure 3-2 B). This suggests that HO-1 mediated antioxidant signaling 
pathway is induced following NAC therapy.  
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Figure 3-2 Plasma HO-1(A) and ferritin (B) levels in plasma samples from CCALD 
patients increased significantly before and after NAC treatment (n=11); means of each 
group are represented by lines; (A) p < 0.001, paired t-test; (B) p<0.01, paired t-test . 
 
3.3.3 Plasma concentrations of HO-1 and ferritin prior to HSCT are highly 
correlated 
 
If HO-1 and ferritin are in the same signaling pathway, we hypothesized that there should 
be a good correlation between plasma levels of these proteins. In the 11 patients with 
paired plasma samples collected prior to and after NAC treatment, Pearson’s correlation 
coefficient r was found to be 0.74 (p<0.0001) between plasma levels of HO-1 and ferritin 
as shown in Figure 3-3. The significant correlation observed proves the close relationship 
between HO-1 and ferritin. Moreover, a clear separation was observed in the distribution 
of HO-1 and ferritin levels indicating the values to be higher in POST-NAC-1 samples 
compared to PRE-NAC samples. 
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Figure 3-3 Correlation between plasma HO-1 and plasma ferritin in CCALD patients for 
PRE-NAC and POST-NAC-1 samples prior to HSCT (n=11). Pearson's correlation r is 
equal to 0.74, p value <0.0001 with two tailed t test. 
 
3.3.4 Plasma concentrations of HO-1 and ferritin prior and after HSCT 
procedures 
Since HSCT procedures and various chemotherapy agents are known as interfering 
factors, we pursued to examine the HO-1 and ferritin levels in patients all along the 
procedure. In total, plasma samples of four time points were analyzed: PRE-NAC (-12 
day), POST-NAC-1 (-8 day), POST-NAC-2 (+7 day), POST-NAC-3 (+21 day). Among 
these samples, PRE-NAC and POST-NAC-1 were sampled prior to HSCT procedure 
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while POST-NAC-2 (+7 day) and POST-NAC-3 (+21 day) were sampled after HSCT 
procedure (Figure 3-4).  
 
Interestingly, plasma HO-1 levels were observed to be induced significantly after NAC 
dosing (p<0.01, POST-NAC-1 compared to PRE-NAC, Dunnett’s test following 
ANOVA). And HO-1 levels were sustained all through the HSCT procedure. The mean 
HO-1 levels for PRE-NAC, POST-NAC-1, POST-NAC-2 and POST-NAC-3 were found 
to be 2.7±0.3, 8.6±0.9, 9.4±1.9 and 10.3±0.8 ng/ml respectively (Figure 3-4 A).    
 
The plasma levels of ferritin turned to be another interesting story. Ferritin levels is not 
only increased following the NAC administration but was also induced by HSCT 
procedure. The mean plasma levels of ferritin for PRE-NAC, POST-NAC-1, POST-
NAC-2 and POST-NAC-3 were found to be 33.0±8.6, 135.4±21.7, 2305.0±578.9 and 
5557.0±1181.0 ng/ml respectively (Figure 3-4 B). Note that PRE-NAC and POST-NAC-
1 were sampled before HSCT and POST-NAC-2 and POST-NAC-3 were sampled after 
HSCT. 
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Figure 3-4  HO-1(A) and ferritin (B) levels in plasma samples from CCALD patients 
prior to and after HSCT procedure (n=10~17); means of each group are represented by 
lines; one way ANOVA was used to compare HO-1 (A) and ferritin (B) levels for all 
sampling time point, p<0.0001 (A) and p<0.0001 (B); Dunnett's multiple comparison test 
was used to compare the sampling time point during NAC treatment with PRE-NAC 
levels, p<0.01 for all other comparisons except ferritin levels between PRE-NAC and 
POST-NAC-1 (p<0.05). 
 
3.3.5 NAC increases HO-1 mRNA and protein levels in human fibroblasts 
 
To exclude multiple interfering factors in HSCT procedures and to investigate the sole 
influence of NAC on HO-1 expression, we also designed and performed in vitro cell 
studies. Human fibroblast cells derived from non-CCALD control were used. NAC 
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Fibroblast cells were incubated with NAC (10-100 µM) for 4 hrs. mRNA levels of HO-1 
was examined using real time PCR and protein levels by ELISA. Interestingly, at all 
incubation concentrations and at both mRNA and protein levels, the HO-1 levels were 
found to be significantly higher than the baseline (p<0.001 for both mRNA and protein). 
Figure 3-5 showed a representative graph showing increased HO-1 expression following 
incubation with NAC. 
 
 
Figure 3-5 HO-1 expression (mRNA and protein levels) in human fibroblast cell line 
following NAC treatment (n=3). ANOVA was used to compare HO-1 mRNA and protein 
levels across treatments, p<0.001 for both comparisons. Dunnett's test was used to 
compare the treatments of different concentrations of NAC with control, **p<0.01. 
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3.4 Discussion 
 
Plasma HO-1 concentrations have been measured extensively in clinical studies as 
surrogate biomarkers. However there was wide variation in the reported concentration of 
HO-1 in plasma. HO-1 levels in control patients were reported to be 1.11 (median, range 
0.63-2.06) ng/ml (Bao et al., 2010),  1.34 (median, range 0.81-2.29) ng/ml (Bao et al., 
2012), and 20±3 ng/ml (mean±SEM) (Zager et al., 2012) depending on different 
detection methods. In our study, we performed assay validation and calibration in 
collaboration with Enzo Life Sciences (MI, USA) before the sample analysis. Since the 
commercial kit was not validated for plasma, we modified the procedure, by using a 
different sample diluent, which increased the detection of HO-1 and gave us a more 
reliable measure. Using this procedure, HO-1 level in normal human plasma was found to 
be 4.05± 0.5. The basal plasma HO-1 level for CCALD patients without any treatment 
(PRE-NAC samples) was observed to be 2.7±0.3 ng/ml. However, since we did not have 
any age and sex matched controls, no further conclusion could be drawn. . Future studies 
enrolling matched controls would be quite useful to compare the basal levels of HO-1 in 
CCALD patients with controls. 
 
NAC is administered at approximately 6000-9000 mg per day for CCALD patients (20-
30kg weight), with each dose administered at levels similar to what is recommended for 
treatment for acetaminophen overdose. Thus the NAC exposure in CCALD patients in 
this study is way more than that dosed in patients with acetaminophen overdose. NAC is 
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dosed in the CCALD patients for more than 100 days while it is only typically dosed in 
patients with acetaminophen overdose for 72 hrs (Kociancic and Reed, 2003). In addition, 
this exposure is higher than what is previously reported for other chronic applications of 
NAC. Long-term NAC therapy is reported to be at 600 mg daily oral dose (Decramer et 
al., 2005) in chronic obstructive pulmonary disease and at 1200-3600mg daily oral dose 
(Mardikian et al., 2007) in treating cocaine-dependent patients.  
 
Here I report for the first time increased plasma HO-1 levels in CCALD patients 
following high exposure of NAC. However we do acknowledge that there are multiple 
factors that can interfere with our observation. During the preparatory regimen of HSCT 
(-11 day till -8 day), NAC and Campath-1H were dosed to the CCALD patients. Thus the 
influence of Campath-1H on plasma HO-1 cannot be ruled out in our study due to the 
limitation of the study design although no previous reports have reported any relationship 
between HO-1 and Campath-1H.  To rule out this possibility, we designed and performed 
the in vitro cell studies to examine the relationship solely between NAC and HO-1 
expression as shown in Figure 3-5. Both mRNA and protein levels of HO-1 were found 
to be increased following the incubation of NAC at three different concentrations of 10, 
50 and 100 µM. Interestingly, NAC at 50 µM in vitro turned out to induce maximal HO-1 
expression, which is within the range of pharmacokinetic NAC plasma concentrations in 
CCALD patients (Holmay et al., 2012).  
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All through the HSCT procedure, HO-1 levels were found to be consistently high 
following NAC administration although several interfering factors exist for POST-NAC-
2 and POST-NAC-3 time points. This can occur due to two reasons. Either, the HO-1 
induction by NAC became saturated at the maximum level after the first few days or that 
the turn-over rate of HO-1 protein is such that we couldn’t see an apparent increase in 
HO-1.  
 
The induction of HO-1 can be helpful for CCALD patients undergoing HSCT in multiple 
ways. Firstly, HO-1 induction in the brain was shown to be closely related to 
neurodegenerative disorders such as Alzheimer’s, Parkinson’s and multiple sclerosis 
(Schipper, 2004). Although the expression of HO-1in the brain is normally confined to a 
small subset of neuronal and glial cells in the CNS, HO-1 expression in these cells is 
highly inducible and can exert antioxidant and anti-inflammation effects to slow down 
the disease progression. Secondly, induction of HO-1 is possibly beneficial to the HSCT 
procedure. Reports have shown that induction of HO-1 levels in liver/bowel tissues 
improved overall survival and reduced acute graft-versus-host disease (aGVHD) rates in 
mouse aGVHD models during bone marrow transplantation (Gerbitz et al., 2004, Ewing 
et al., 2007).  
 
The induction of HO-1 in cells and tissues may be harmful in spite of the general 
understanding of cytoprotective effects of HO-1. Excessive HO-1 induction was found to 
associate with tissue iron sequestration and mitochondrial insufficiency (Schipper et al., 
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2009b). Inhibition of HO-1 hyperactivity in glial cells prevented iron deposition which 
was indicated as therapeutic target in Alzheimer’s disease (Schipper et al., 2009a). These 
results indicate that the HO-1 concentrations should be kept within reasonable therapeutic 
range. Our observation of saturated induction of HO-1 levels following NAC 
administration may be beneficial, as excessive HO-1 expression is harmful. In summary, 
modulation of appropriate HO-1 induction is a crucial for mitigating oxidative stress.  
 
Ferritin, as one the downstream product of HO-1, was also induced following the 
administration of NAC. The concentrations of ferritin were observed to be linearly 
correlated with increased HO-1 before HSCT procedures. However, ferritin was also 
highly influenced by the HSCT procedure as shown in Figure 3-4. This observation is 
consistent with previous finding that ferritin is highly induced by bone marrow 
transplantation (Or et al., 1987). 
 
3.5 Conclusion 
 
In our study, the survival of CCALD patients increased with NAC adjuvant therapy. 
Following NAC administration, there was significant increase in HO-1 and ferritin 
concentrations in CCALD patients’ plasma. With the observation of increase in survival 
and increase in HO-1 plasma concentrations, we hypothesized that HO-1 played crucial 
roles in mediating the cytoprotective effects of NAC in CCALD patients and this increase 
in HO-1 is reasonably beneficial for the CCALD patients. 
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In addition, our in vitro results suggest HO-1 as a cell signaling mediator of NAC-
induced protection. These results indicate that HO-1 and ferritin contribute to the 
cytoprotective benefits of NAC in CCALD patients.  
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CHAPTER 4 
N-ACETYLCYSTEINE PROVIDES CYTOPROTECTION IN 
MURINE OLIGODENDROCYTES THROUGH HEME 
OXYGENASE-1 ACTIVITY 
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4.1 Introduction 
 
Oxidative stress in the CNS plays a significant role in the pathophysiology of 
neurodegenerative disorders. ROS produced during CNS oxidative stress can lead to 
damage of intracellular DNAs, proteins and lipids resulting in cell death (Shukla et al., 
2011b). Oligodendrocytes are CNS cells that produce myelin sheath around neurons. 
They are highly vulnerable to oxidative stress, which can disrupt their maturation or 
cause cell death (Jana and Pahan, 2007, French et al., 2009). Death of oligodendrocytes 
has been considered as an early event in CNS demyelination and neurodegeneration 
(Zhang et al., 2013). Due to the close relationship between oxidative stress induced 
damage and neurodegeneration, reduction in oxidative stress is being explored as an 
approach to slow down progression of various neurodegenerative diseases as 
demonstrated in recent in-vivo and clinical studies (Ahmad et al., 2012, Goes et al., 2013, 
Jin et al., 2013). 
 
NAC is a thiol-containing antioxidant, available both as FDA-approved products and 
dietary supplements. NAC is indicated as an inhaled agent for mucolysis in cystic fibrosis 
(Mucomyst®) and intravenously as an antidote for acetaminophen overdose 
(Acetadote®) (Heard and Green, 2012b, Rushworth and Megson, 2013a). Because of 
NAC’s   apparent successful clinical use in a wide range of diseases, several mechanisms 
have been proposed for its beneficial antioxidative and anti-inflammatory properties.  
These include direct free radical scavenging, metal ion chelation, and as a precursor for 
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synthesis of the endogenous GSH (Schroder et al., 1993, Dodd et al., 2008). In addition, 
one of the mechanisms of action of NAC may involve the regulation of tissue protective 
genes that reduce damage inflicted by reactive oxygen species (ROS) (Zafarullah et al., 
2003). Among the cytoprotective proteins, HO-1is induced by thiol-containing 
biomolecules such as lipoic acid and NAC (Ogborne et al., 2005, Xu et al., 2013). This 
enzyme catalyzes the oxidative metabolism of heme to form equimolar amounts of 
biliverdin (which is then converted to bilirubin), carbon monoxide (CO), and free iron; all 
of which have anti-oxidative properties (Abraham et al., 2007, Abraham and Kappas, 
2008). Thus HO-1 may contribute to the cytoprotective effects of NAC that might be of 
particular significance during inflammatory processes triggered by oxidative stress.  
 
Despite previous extensive research works, the exact mechanisms by which NAC exert 
its cytoprotective effects on oligodendrocytes remain poorly elucidated. In this study, we 
have characterized the mechanisms underlying the cytoprotective properties of NAC in 
oligodendrocytes, under conditions of oxidative stress. 
 
4.2 Materials and methods 
 
4.2.1 Materials 
 
Dulbecco's Modified Eagle Medium (DMEM) high glucose medium, fetal bovine serum 
(FBS), and antibiotic-antimycotic (AA), phosphate buffered saline (PBS), Trypsin-EDTA 
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and fluorescent CM-H2DCFDA probe were obtained from Life Technologies, (CA, 
USA). 7-AAD fluorescent probe was from BD Biosciences (CA, USA). L-buthionine-
(S,R)-sulfoximine (BSO), hydrogen peroxide (H2O2), N-acetyl-L-cysteine (NAC), 
sucrose, mannitol and ethylene glycol-bis(2-aminoethylether)-N,N,N´,N´-tetra acetic acid 
(EGTA) were purchased from Sigma-Aldrich (MO, USA). HEPES 1M solution was from 
Mediatech (VA, USA). Chromium mesoporphyrin IX chloride (CrMP) was obtained 
from Frontier Scientific (UT, USA).  Acetonitrile, ammonium formate in the mobile 
phase were purchased from Fisher Scientific (PA, USA). Stock solutions of compounds 
were made in PBS. Culture medium was used to prepare working solutions. The pH of 
the NAC stock solution in PBS (10mM) was adjusted to 7.4 and filtered prior to making 
further dilutions. 
 
4.2.2 Cell culture and experimental conditions 
 
Immortalized murine oligodendrocyte cell lines, 158N (normal) and proteolipid protein 
mutant 158JP (Jimpy) were a generous gift from Dr. Ghandour (Baarine et al., 2009a).  
158N and 158JP were derived from normal and Jimpy mice respectively, showing 
characteristics of well-differentiated oligodendrocytes. 158JP oligodendrocytes 
demonstrated a mutation on proteolipid protein PLP/DM20 which caused premature 
death of oligodendrocytes and severe CNS demyelination (Knapp et al., 2009). 158JP 
cells were observed to have significantly higher spontaneous ROS and superoxide anion 
production compared to 158N cells (Baarine et al., 2009a). Approximately 10
6 
cells were 
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seeded on 75 cm
2 
culture flasks (Corning, NY, USA) in DMEM high glucose medium 
supplemented with 5% FBS and 1% AA. Cells were incubated overnight in 37 °C 
incubator with 5% CO2. At the onset of experiments, cells were seeded on 24-well or 96-
well plates and cultured overnight to achieve 80% confluence. Cells were treated with 
500μM H2O2 to mimic oxidative stress conditions. For all experiments, NAC, at 
concentrations ranging from 50µM to 500µM, was co-incubated with H2O2 for 24 hours. 
For inhibitor studies, 50µM BSO (GSH inhibitor) or 30µM CrMP (HO-1 inhibitor) was 
added 20 minutes prior to addition of NAC with H2O2. For all experiments, cells in 
culture medium served as negative control.  
 
4.2.3 Cell survival assays 
 
Cell survival following various experimental treatments was quantified using 
colorimetric assays on treated cells cultured in 96-well plates. CellTiter 96
® 
Aqueous 
(Promega, MI, USA) and Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) were used to 
determine cell viability following manufacturer’s protocol. 
 
4.2.4 Evaluation of intracellular ROS 
 
Evaluation of intracellular ROS was performed by fluorescence-activated cell sorting 
(FACS) using fluorescent CM-H2DCFDA probes. Briefly, after 24 hours in varying 
conditions, cells seeded on 24-well plates were harvested and washed twice with PBS. 
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The cells were then stained with 1µM CM-H2DCFDA for 5 minutes. The samples were 
subsequently washed twice and resuspended in 250µl PBS containing 5µl 7-AAD 
fluorescent probes for analysis. During acquisition of FACS data, the live cells (negative 
for 7-AAD) were gated and evaluated for ROS with CM-H2DCFDA. 
Further, the fluorescence intensity of CM-H2DCFDA was also gated uniformly to 
designate positive events of CM-H2DCFDA stained cells. The percentage of positive 
stained CM-H2DCFDA was used as the indicator for ROS levels in different treatment 
groups. To compare across different sets of experiments, ROS levels in 158N cells 
incubated with medium were used to normalize across different groups to achieve relative 
ROS levels. 
 
4.2.5 Determination of intracellular GSH 
 
Cells seeded on 24-well plates were subjected to different experimental conditions. At the 
end of incubation, the cells were washed twice with PBS and the harvested cells were 
lysed using lysis buffer (20mM HEPES, 1mM EGTA, 210mM mannitol and 70mM 
sucrose, pH 7.2). 2 ml of methanol was added into 100 µL of cell lysates and vortexed. 
The processed samples were centrifuged at 2500 rpm for 10 minutes at 4 
o
C. The organic 
layer was removed and evaporated under nitrogen gas at 37 
o
C. The samples were 
reconstituted in mobile phase and filtered in vials using nylon acrodisc syringe filters 
(Pall Life Sciences, MI, USA). Intracellular GSH was determined using liquid 
chromatography-mass spectrometry (HPLC-MS) (Agilent Technologies, CA, USA) with 
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series 1100 system consisted of a G1322A degasser, a G1311A quaternary pump, and a 
G1313A autosampler. The electrospray interface is connected to a single quadrupole 
G1946A. The HPLC-MS system was controlled and data were processed using 
Chemstation software (Agilent Technologies, CA, USA). The samples were analyzed 
using selective ion monitoring (SIM) mode and the positive ion for GSH was set at 308 
(m/z). GSH separation  was performed  using a mobile phase consisting of 98% 20mM 
ammonium formate buffer at pH 3.0 and 2% acetonitrile through Agilent ZORBAX 
Eclipse XDB-C18 (3×150mm, 3.5µm) column.  Total cellular protein concentrations 
were analyzed using Quick Start Bradford protein Assay Kit (Bio-Rad, CA, USA) 
according to manufacturer’s protocol. Total GSH concentrations in each group were 
normalized to total protein concentrations to obtain GSH concentrations in µg/mg. GSH 
concentrations in cells incubated with medium served as control and were used to 
normalize across different groups. 
 
4.2.6 Total antioxidant capacity assay 
 
Total antioxidant capacity (TAC) was evaluated by a colorimetric method (Miller et al., 
1993), using Antioxidant Assay Kit from Cayman Chemical (MI, USA). At the end of 
incubation with different experimental conditions, cells seeded on 24-well plates were 
washed twice with PBS, harvested using trypsin-EDTA, lysed and sonicated in ice-cold 
balanced buffer (5mM KH2PO4, 0.9% sodium chloride and 0.1% glucose, pH 7.4). The 
cell lysates were centrifuged and analyzed following the manufacture’s protocol. TAC 
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was expressed as equivalent Trolox concentrations and normalized to total protein 
concentrations determined using the Bradford protein assay in each group. Finally, TAC 
levels in cells incubated with medium served as controls, which were used to normalize 
across different groups.  
 
4.2.7 Statistical data analysis 
 
For all cellular assays, results were expressed as means ± standard error. Data was 
analyzed using ANOVA with a Bonferroni’s correction for multiple comparisons. A p-
value <0.05 was considered significant. Analyses are based on data from three 
independent experiments using different cell passages on different days. 
 
4.3 Results 
 
4.3.1 N-acetylcysteine  decreases ROS formation in oligodendrocytes under 
conditions of oxidative stress 
 
In order to characterize the anti-oxidative properties of NAC, murine oligodendrocytes 
(158N) were incubated either with 500µM H2O2 alone or in combination with increasing 
concentrations of NAC (50-500 µM) for 24 hrs. The cells were then subjected to FACS 
analysis using CM-H2DCFDA probe to analyze intracellular ROS levels. Incubation of 
158N oligodendrocytes with H2O2 resulted in 5.6±0.8 fold increase in ROS levels 
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compared to the control.  Additionally, we observed that co-incubation of the cells with 
both NAC and H2O2 prevented the increase in ROS in a concentration-dependent manner 
(Figure 4-1). 
 
 
Figure 4-1 Incubation with NAC decreased ROS in 158N (A, exogenous ROS, n=3) and 
158JP (B, endogenous ROS, n=3) cells. A) Incubation of 158N cells with H2O2 increased 
ROS levels (as indicated by arrow). Addition of NAC (50-500µM) for 24hrs decreased 
ROS levels as measured by FACS. Medium treated 158N cells were used as control. # # # 
p<0.001 indicates significant difference between H2O2 and control; ** p<0.01, 
***p<0.001; indicate significant difference between NAC+ H2O2 treatments and H2O2 
alone. B) 158N cells and 158JP cells cultured in medium were compared side by side. 
***p<0.001 indicate significant difference in the spontaneous ROS production between 
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158N and 158JP cells. Addition of NAC (25 µM and 100 µM) for 24hrs decreased the 
endogenous ROS levels in 158JP cells. # # p<0.01 indicate significant difference between 
158JP cells in medium and cells treated with NAC. All data were normalized to 158N 
control (ROS levels= percentage of stained cells in each group/percentage of stained 
cells in 158N control). ANOVA followed by Bonferroni test was used for statistical 
analysis. 
 
In parallel, we conducted similar studies in a cell line with endogenous high ROS levels 
due to a mutation in proteolipid protein (158JP).  These cells were observed to 
spontaneously generate higher ROS when compared to158N cells.  The baseline ROS 
levels of 158JP cells were approximately 10-fold compared to 158N cells. We further 
characterized the effect of NAC in scavenging the endogenous ROS in these cells. The 
158JP cells were incubated with NAC at 25μM and 100μM concentration for 24 hrs. 
Interestingly, we observed a significant decrease in baseline ROS levels (from 9.9±1.0 to 
3.7±0.4) in these cells at NAC concentrations as low as 25µM (Figure 4-1 B). However, 
we did not observe a concentration-dependent decrease in ROS with NAC (no observed 
statistical difference between treatments of NAC 25µM and 100µM).  The above results 
indicate that NAC can decrease both exogenous and endogenous ROS in 
oligodendrocytes. 
 
4.3.2 Incubation with NAC improved cell survival in a concentration-dependent 
manner 
  72 
 
We next investigated whether the reduction in ROS resulted in increased cell survival. 
For this purpose, cells were incubated with 500µM H2O2 alone or in combination with 
NAC (50-500µM) for 24hrs and then subjected to cell survival analyses. Exposure of 
158N cells to 500µM H2O2 resulted in approximately 50% cell survival compared to 
control which is considered to be 100%. In contrast, the co-incubation of increasing 
concentrations of NAC (50-500µM) with H2O2 improved cell survival in a concentration-
dependent manner (Figure 4-2). The survival rate in cells co-treated with 250µM NAC+ 
H2O2 was 77.3±1.3% as compared to 52.4±1.6% in cells treated with H2O2 alone 
(p<0.001) . This suggests that NAC plays a cytoprotective role in oligodendrocytes, 
preventing H2O2-induced cell death. 
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Figure 4-2 NAC augmented cell survival under conditions of oxidative stress in a 
concentration dependent manner. Incubation with H2O2 induced cell death in 158N cells 
(as indicated by arrow). Addition of NAC (50-500µM) for 24hrs improved cell survival 
(n=6). Cells in culture medium were used as control. # # # p<0.001 indicate significant 
difference between cells treated with H2O2 and control; ***p<0.001; indicate significant 
difference between NAC+ H2O2 treatment and H2O2 alone. ANOVA followed by 
Bonferroni test was used for statistical analysis. 
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4.3.3 Improved cell survival is attained by increase in intracellular total GSH 
levels 
 
Next we were interested to explore the mechanism underlying the cytoprotective 
properties of NAC. For this we measured the total GSH levels in 158N cells under 
conditions of oxidative stress (500µM H2O2 for 24hrs) with or without the incubation of 
increasing concentrations of NAC (50-500µM for 24hrs). Intracellular GSH in 158N cells 
was found to be 24.3 ±1.3 µg/mg total protein. Further, we observed an increase in total 
GSH levels with increasing concentrations of NAC (Fig 4-3 A). The total GSH increased 
1.7±0.02 fold with 500µM NAC relative to control. Incubation with 500µM H2O2 
resulted in an 80% decrease of intracellular GSH (0.2 ± 0.01 fold of control).  This 
depletion of total GSH was partially restored by co-incubation with 500µM each of NAC 
and H2O2 (0.58±0.04 fold of control). It is noteworthy that this nominal increase in GSH 
was sufficient to increase cell survival by ~80% (Figure 4-2). 
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 Figure 4-3 LC-MS analysis of intracellular reduced form of GSH in 158N (A, n=3) and 
158JP cells (B, n=3). A) NAC (50, 100 and 500 µM, 24hrs) increased GSH in 158N cells 
(**p<0.01, ***p<0.001) compared to control. Incubation of 158N cells with H2O2 (500 
µM, 24hrs) reduced intracellular GSH levels significantly (***p<0.001). Upon NAC 
treatment, GSH levels were replenished significantly in a concentration-dependent 
manner (# p<0.05). ANOVA followed by Bonferroni test was used for statistical analysis. 
3B) NAC (50µM, 24hrs) significantly increased GSH in 158JP cells (**p<0.01). 
Student’s t-test was used for statistical analysis. 
 
Intracellular GSH in 158JP cells was observed to be 29.1±4.9 µg/mg total protein at 
baseline. Despite high intracellular ROS, the GSH level was higher in these cells 
compared to normal oligodendrocytes. This is consistent with previous observations 
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(Baarine et al., 2009a). In order to examine whether NAC can replenish GSH in cells 
with endogenous high ROS levels, we measured the total GSH levels in 158JP cells 
following incubation with a low concentration of NAC (50 µM). Remarkably, incubation 
with NAC increased the total GSH levels by 3.9±0.4 fold as compared to control (Figure 
4-3 B). 
 
4.3.4 Inhibition of GSH synthesis blocked cytoprotective effects of NAC 
 
In order to further analyze the role of intracellular GSH in mediating the cytoprotective 
effects of NAC, we performed inhibitor studies in 158N cells using 50M of BSO, a 
well-known GSH synthesis inhibitor (Drew and Miners, 1984). The 158N cells were co-
incubated with H2O2, NAC or BSO in different combinations as indicated for 24hrs and 
then subjected to cell survival assays. Incubation of cells with 500µM H2O2 resulted in 
52.0±1.6% cell death. Supplementation of 250µM NAC increased cell survival to 
79.7±1.5% (Figure 3-4). Addition of BSO blocked cell survival (decreased to 71.4±1.8 
%, p<0.05). These results indicate that inhibition of GSH synthesis reduces the 
cytoprotective effects of NAC.  
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Figure 4-4  Inhibition of GSH synthesis blocked cytoprotective effects of NAC. Cell 
survival assays were performed in presence of GSH synthesis inhibitor (BSO) in 158N 
cells (n=6). *** p<0.001 indicate significant cell death following H2O2 (500 µM, 24hrs) 
treatment compared to control. ### p<0.001 indicate the cytoprotective effects of NAC 
(250µM, 24hrs) compared to H2O2 treated group. Δ p<0.05 indicate significant 
difference in cell survival between cells treated with NAC+H2O2 +BSO compared to 
NAC+H2O2 co-treatment group. ## p<0.01 indicate that observed cell survival in 
presence of BSO was higher than H2O2 treated group. ANOVA followed by Bonferroni 
test was used for statistical analysis. 
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4.3.5 Heme oxygenase-1 is a potential mediator of the cytoprotective effects of 
NAC 
 
In order to further delineate the mechanisms by which NAC causes cytoprotection, we 
investigated the role of a well-known inducible cytoprotective protein, heme oxygenase-1 
(HO-1) Towards this end, we performed inhibitor studies in 158N cells using chromium 
mesoporphyrin IX (CrMP, 30M), a selective inhibitor of HO-1 activity (Appleton et al., 
1999).  The 158N cells were co-incubated for 24 hrs with H2O2, NAC or CrMP in 
different combinations as indicated and then subjected to cell survival assays. Incubation 
of NAC (50-500µM) with H2O2 (500µM) showed improved cell survival (Figure 4-5, 
solid grey bars) compared to H2O2 treated group. However, addition of CrMP resulted in 
a significant decrease in cell survival (Figure 4-5, checkered bars) with the survival rate 
being comparable to the H2O2 treated group. This indicates that the cytoprotective 
properties of NAC were abolished by CrMP treatment. Interestingly, the cytoprotective 
effects of NAC at 500µM was not affected by the addition of CrMP, suggesting either the 
incomplete inhibition of HO-1 activity or that cytoprotection by NAC at higher 
concentrations utilized mechanisms other than HO-1 activity. 
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Figure 4-5 HO-1 plays a vital role in the cytoprotective action of NAC. Cell survival 
assays were performed in presence of HO-1 activity inhibitor (CrMP) (n=6). *** 
p<0.001 indicate significant cell death following H2O2 treatment compared to control. 
##p<0.01 and ###p<0.001 indicate the cytoprotective effects of NAC (50-500 µM, 24hrs, 
solid grey bars) compared to H2O2 treated group. The addition of CrMP abolished the 
cytoprotective effects of NAC (50-250 µM, 24hrs) as shown (checkered bars).*p<0.05, 
ΔΔ p<0.01 indicate significant decrease in cell survival rate after the addition of CrMP 
(30 µM) in NAC+ H2O2 co-treated group. ANOVA followed by Bonferroni test was used 
for statistical analysis. 
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In order to further confirm that CrMP in fact inhibits the downstream antioxidant activity 
of HO-1, we analyzed the total antioxidant capacity (TAC) in these experimental 
conditions (Figure 4-6). This kit measures the combined antioxidant activities of 
vitamins, proteins, lipids, GSH, uric acid, etc. present in cell lysates. The baseline TAC 
levels in 158N cells were measured as equivalent to 0.28 ±0.01 µmol/mg total protein of 
Trolox. Upon incubation with NAC (100µM, 24 hrs), TAC levels were increased to 
0.34±0.02µmol/mg total protein of Trolox (1.2±0.07 fold of control). In contrast, the 
incubation of H2O2 (500µM) decreased TAC levels to 0.13±0.03 µmol/mg total protein 
of Trolox (0.45±0.1 fold of control), indicating oxidative stress in the cells. Co-treatment 
of H2O2 (500µM) and NAC (100µM) significantly increased the TAC approximately to 
baseline levels (0.24±0.03 µmol/mg total protein of Trolox). However, addition of CrMP 
(30µM) along with NAC and H2O2 resulted in significant decrease in TAC to levels 
comparable to oxidative stress conditions. These results are in line with our observation 
that inhibition of HO-1 activity can effectively abolish the cytoprotective effects of NAC.  
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Figure 4-6 Total antioxidant capacity (TAC) assays in presence of HO-1 activity 
inhibitor (CrMP) (n=3). **p<0.01 indicate that H2O2 treatment (500 µM, 24hrs) 
significantly decreased the total amount of antioxidants in cell lysates compared to 
control. # p<0.05 indicate that the addition of NAC (100 µM, 24hrs) increased TAC of 
the system compared to H2O2 only group. Δ p<0.05 indicate that the addition of CrMP 
(30 µM) inhibited the effects of NAC. ANOVA followed by Bonferroni test was used for 
statistical analysis. 
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4.4 Discussion 
 
In this study, we describe the mechanisms underlying the cytoprotective effect of NAC in 
oligodendrocytes in conditions of oxidative stress. Oxidative stress is associated with 
depletion of intracellular GSH resulting in decreased cell survival (Aoyama and Nakaki, 
2013). NAC is a prodrug that increases biosynthesis of GSH levels, but we show for the 
first time that the cytoprotective properties of NAC are, in part, dependent on the activity 
of the antioxidant protein HO-1.  
 
Oligodendrocytes are crucial glial cells in the CNS that are involved in the formation of 
myelin sheath (Harauz et al., 2004).  Loss of the myelin sheath, also called 
demyelination, is a hallmark of several neurodegenerative diseases including multiple 
sclerosis and X- linked ALD. Although the precise mechanism by which demyelination 
occurs has not been determined, there are reports describing the presence of oxidative 
stress markers in demyelinating lesions of the patients’ brain (Smith et al., 1999). 
Interestingly, oligodendrocytes are the most sensitive cell type in the brain to oxidative 
stress in vitro compared to both astrocytes and neuronal cells (Smith et al., 1999) and the 
death of these cells is an early event in a CNS demyelination rat model (Zhang et al., 
2013). These reports indicate that mitigating oxidative stress in oligodendrocytes may 
have a role as therapy for neurodegenerative disorders. Antioxidants such as NAC, lipoic 
acid and tocopherol (Vitamin E) have been widely investigated in diseases associated 
with oxidative stress such as diabetes, brain injury, multiple sclerosis and X-ALD 
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(Gilgun-Sherki et al., 2004, Satpute et al., 2010, Lopez-Erauskin et al., 2011b, Hegazy et 
al., 2013, Ishaq et al., 2013). In this study, we utilized a mutated oligodendrocyte cell 
line, 158JP that showed endogenously high levels of spontaneous ROS as well as a 
normal oligodendrocyte cell line 158N, in which H2O2 was exogenously used to mimic 
oxidative stress. 
  
NAC is an effective free radical scavenger as well as a precursor for intracellular cysteine 
and GSH. It helps maintain intracellular levels of the antioxidant GSH by providing the 
rate-limiting substrate cysteine for GSH synthesis (van Zandwijk, 1995a, Rushworth and 
Megson, 2013a). GSH is an endogenous non-enzymatic scavenger of free radicals, and 
depletion of GSH is an indicator of oxidative stress (Wu et al., 2004a).  Using 
1
H 
magnetic resonance spectrometry, Low GSH levels are found in brain tissues of patients 
with multiple sclerosis (Choi et al., 2011b). Further, impaired GSH biosynthesis is found 
in Parkinson’s disease (Zhou and Freed, 2005b, Choi et al., 2006b). And impaired 
utilization of GSH is observed in Alzheimer’s disease (Lovell et al., 1998). GSH levels in 
blood cells of X-ALD patients are also observed to be lower compared to control (Petrillo 
et al., 2013a). The increased interest in using NAC for a wide range of unrelated diseases 
necessitates the need to better understand its pharmacology. Our observation that NAC 
replenished GSH and consequently improved glial cell survival under conditions of 
oxidative stress is consistent with previously published report (Badisa et al., 2013). 
Further, we confirmed this observation using an inhibitor of GSH synthesis (BSO). BSO 
is an established specific inhibitor of glutamate cysteine ligase (GCL, the rate-limiting 
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enzyme in GSH synthesis) and treatment with BSO reduced levels of intracellular GSH 
(Dusre et al., 1989, Zaman et al., 1995).  
 
Moreover, our study documents the critical role of HO-1 in mediating the cytoprotective 
effects of NAC. HO-1 has been proposed as a potent protective protein against oxidative 
stress in both in-vitro neuronal cells (Le et al., 1999) and in-vivo oxidative stress mouse 
models of ischemia (Panahian et al., 1999) and Huntington's disease (Colin-Gonzalez et 
al., 2013). Further, impairment of HO-1 expression or post-transcription modification 
plays an important role in neurodegenerative disorders including Parkinson’s disease 
(PD) (Chien et al., 2011) and Alzheimer’s disease (AD) (Barone et al., 2012). Although 
the exact role of HO-1 is still under debate, upregulation of HO-1 is assumed to be an 
early adaptive event in response to stress (Barone et al., 2013).  
 
HO-1 is highly inducible by a variety of chemical or physical agents (Chien et al., 2011). 
For example, the HO-1 signaling pathway is under a feedback regulation wherein the 
accumulation of its substrate, heme, induces the expression of HO-1. Other inducers 
include heavy metals, endotoxin, heat shock, inflammatory cytokines, and prostaglandins 
that directly or indirectly generate ROS (Choi and Alam, 1996, Ryter and Choi, 2005). In 
addition to oxidative stress related inducers, HO-1 is also found to be induced and 
mediate the antioxidant effects of aspirin (Grosser et al., 2003, Sparatore et al., 2009) and 
statins (Grosser et al., 2004, Hinkelmann et al., 2010, Kim et al., 2012, Li et al., 2012). 
Interestingly, HO-1 is also found to mediate the antioxidant effects of a variety of 
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antioxidants such as α-lipoic acid (Ogborne et al., 2005, Lin et al., 2013), S-adenosyl 
methionine (Erdmann et al., 2008), curcumin and resveratrol (Son et al., 2013), L-
methionine (Erdmann et al., 2005) and 3-O-caffeoyl-1-methylquinic acid (Kweon et al., 
2004).  Our results with CrMP also demonstrate HO-1 is an important mediator of the 
cytoprotective action of NAC in oligodendrocytes, which in turn, correlated with a 
decrease in total antioxidant capacity (TAC).  NAC has been shown to elevate HO-1 
levels through enhancement of Brahma-related gene 1 (Brg1) in cardiac tissues (Xu et al., 
2013). In another study conducted in diabetic rats, it was shown that the cardiac 
protective effects of antioxidants NAC and allopurinol were abolished with HO-1 
inhibitors, showing the important role of HO-1 as a signaling mediator (Mao et al., 2013).  
This is in contrast to the several studies were NAC was used to attenuate HO-1 
expression (Rensing et al., 1999, Kim et al., 2013). This is because NAC is a free radical 
scavenger (Aruoma et al., 1989, Cotgreave, 1997). By removing free radicals, NAC can 
decrease HO-1 expression induced by higher ROS levels.  
 
Previously in our lab, we have determined the HO-1 promoter activity in NIH3T3-HO-1-
luc cells using in vivo bioluminescence imaging (Sparatore et al., 2009). Using the same 
model, treatment with NAC (50-1000µM) revealed a signal towards an increase in 
luciferase activity as early as 2 hours after NAC treatment, which was sustained up to 8 
hours and decreased to below baseline levels by 24 hours (Erdman. K, unpublished data). 
Recently treatment of rat retinal ganglion cells with NAC showed an increasing trend of 
HO-1 expression in during normal redox conditions (~1.5 fold) (Majid et al., 2013). 
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These data indicate the ability of NAC to induce HO-1 expression under optimal 
conditions, and here we demonstrate HO-1 as a mediator of NAC action in protecting 
oligodendrocytes from oxidative stress damage.  
 
4.5 Conclusions 
 
In summary, we investigated the mechanisms by which NAC mitigates oxidative stress in 
oligodendrocytes. We have demonstrated that HO-1 is a signaling mediator critical for 
NAC action. NAC reduces ROS, supplements intracellular GSH as well as protects 158N 
cells thereby improving survival in conditions mimicking oxidative stress. Moreover, 
NAC boosted GSH levels in 158JP oligodendrocytes which have high ROS levels. 
Notably this antioxidant property was evident in these mutant cells at lower NAC 
concentrations compared to normal oligodendrocytes highlighting the therapeutic benefit 
of NAC in genetic conditions causing oxidative stress. In addition to its role as a free 
radical scavenger, our study shows other important mechanisms of NAC action, which 
may permit more effective use of this antioxidant in disorders with oxidative stress.  
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CHAPTER 5 
N-ACETYLCYSTEINE REVERSES MITOCHONDRIAL 
TOXICITY OF VERY LONG CHAIN FATTY ACIDS IN 
MURINE OLIDODENDROCYTES 
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5.1 Introduction 
 
Mutations in ABCD1, the peroxisomal membrane transporter of very long chain fatty 
acid (VLCFA), cause ALD. Since degradation of VLCFAs requires these molecules to be 
transported into peroxisomes to facilitate β-oxidation, mutations in ABCD1 transporter 
impair regular degradation of VLCFAs and cause intracellular accumulation of VLCFAs. 
Igarashi et al. for the first time reported observation of increased levels of VLCFAs such 
as hexacosanoic acid (C26:0) in the brain and adrenal tissues of ALD patients (Igarashi et 
al., 1976). However, the detailed pathogenesis is largely unknown. CCALD  is one type 
of ALD with manifestations of demyelination and CNS neurodegeneration affecting boys 
at 4-10 years old (Steinberg et al., 1993). Currently only limited therapeutic interventions 
are available to CCALD patients. Thus better understanding of the contribution of 
VLCFAs in CCALD disease pathology could greatly facilitate the research towards 
therapies. 
 
It is known that degradation of long-chain fatty acids requires the collaboration of 
mitochondria in addition to peroxisomes (Hashimoto et al., 1999). Recently, growing 
evidence indicates a close relationship between VLCFAs accumulation and 
mitochondrial dysfunction: the rate of peroxisomal VLCFA β-oxidation is affected by 
mitochondrial dysfunction (McGuinness et al., 2003) and decreased mitochondria 
function parameters were observed in ALD in vitro and in vivo models (Fourcade et al., 
2008, Hein et al., 2008, Fourcade et al., 2013, Lopez-Erauskin et al., 2013). Mitochondria 
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are involved in scavenging free radicals and store antioxidants such as GSH and harbor 
detoxifying enzymes (Schrader and Yoon, 2007). It plays a central role in initiating and 
regulating programmed cell death or apoptosis (Wang and Youle, 2009). Thus even if the 
primary cause of a pathology is unrelated to mitochondria, mitochondrial dysfunction is a 
significant secondary factor in determining clinical outcomes (Smith and Murphy, 2011). 
Among the arsenal of protective mechanisms, mtGSH has emerged as the main line of 
defense by the maintenance of optimal redox environment within the organelle 
(Fernandez-Checa et al., 1998). As shown in various pathological conditions, loss of 
mtGSH pre-disposed the cell towards oxidant-induced injuries including cerebral 
ischemia (Anderson and Sims, 2002) and hypoxia (Lluis et al., 2005). Thus strategies 
aimed at the restoration of mtGSH could possibly de-sensitize the cells to VLCFAs and 
in turn improve cell survival.  
 
Research into the restoration of mitochondrial function has been widely reported using 
antioxidants (Fedotcheva et al., 2012, Singh et al., 2012, Nguyen et al., 2013). NAC is a 
well-known antioxidant, precursor for the crucial intracellular antioxidant GSH (van 
Zandwijk, 1995b) that protects  against damage from free radicals (Wu et al., 2004b). 
NAC was shown to effectively suppress lipid peroxidation induced mitochondrial injury 
in primary neuronal cells (Arakawa et al., 2006). And it was shown to play a protective 
role through targeting mitochondria in neurodegenerative disorders such as Alzheimer’s 
disease (Robinson et al., 2011) and Parkinson’s disease (Bagh et al., 2008).  
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In this study, we investigated the mitochondrial toxicity induced by VLCFAs and focused 
specifically on its influence on the change of mtGSH in 158N cells. Further, an effort was 
made to test the possible therapeutic effects of NAC on reversing the toxicity of VLCFAs.  
 
5.2 Materials and methods 
 
5.2.1 Materials  
 
Dulbecco's Modified Eagle Medium (DMEM) high glucose media, fetal bovine serum 
(FBS), and antibiotic-antimycotic (AA), phosphate buffered saline (PBS), Trypsin-EDTA 
and fluorescent CM-H2DCFDA probes and MitoSOX
TM
 probes were obtained from Life 
Technologies, (CA, USA) and 7-AAD was from BD Biosciences (CA, USA).  
 
Hexacosanoic acid (C26:0), acrolein, N-acetyl-L-cysteine (NAC), sucrose, mannitol and 
ethylene glycol-bis (2-aminoethylether)-N, N, N´, N´-tetraacetic acid (EGTA) were 
purchased from Sigma-Aldrich (MO, USA). HEPES 1M solution was from Mediatech 
(VA, USA). Hexacosanoic acid was dissolved in ethanol (heated to 37 °C) at 2.5mM as 
stock solution. The following validated kits were used: Cell Counting Kit-8 from Dojindo 
(Kumamoto, Japan), JC-1 Mitochondrial Membrane Potential Assay Kit and Glutathione 
Assay Kit from Cayman Chemical (MI, USA), Mitochondria Isolation Kit for Cultured 
Cells from (Thermo Scientific, IL, USA), Quick Start Bradford Protein Assay from Bio-
Rad (CA, USA) and ATPlite™ Luminescence Assay System from PerkinElmer (MA, 
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USA). Stock Solutions of all chemicals were made and culture medium was used to 
prepare working solutions. The pH of the NAC stock solution (10mM) was adjusted to 
7.4 and filtered prior to making further dilutions. 
 
5.2.2 Cell culture and treatments 
 
An immortalized murine oligodendrocyte cell line, 158N (normal) was a generous gift 
from Dr. Ghandour (Baarine et al., 2009b). Around 10
6 
cells were seeded on 75 cm
2 
culture flasks (Corning, NY, USA) in DMEM high glucose media supplemented with 5% 
FBS and 1% AA. Cells were incubated overnight in 37 °C incubator with 5% CO2. For 
experimental set up, cells were seeded on 75 cm
2 
culture flasks; 24-well or 96-well plates 
and cultured overnight to get 80% confluence. Cells were challenged for 24hrs with 1-
100 μM Hexacosanoic acid (C26:0), to mimic disease conditions. NAC, at concentrations 
ranging from 50µM to 500µM, was co-incubated with C26:0 for 24 hours to examine the 
therapeutic effects of NAC.  
 
5.2.3 Cell survival assays 
Cell survival following various experimental treatments was quantified using 
colorimetric assays on treated cells cultured in 96-well plates. Cell Counting Kit-8 from 
Dojindo was used to determine the cell viability following manufacturer’s protocol. 
 
5.2.4 Evaluation of intracellular ROS   
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Evaluation of intracellular ROS was performed by Fluorescence Assisted Cell Sorting 
(FACS) using fluorescent CM-H2DCFDA probe. Briefly, after 24 hours of experimental 
treatments, cells seeded on 24-well plates were harvested and washed twice with PBS. 
The cells were then stained with 1µM CM-H2DCFDA for 5min. The samples were 
subsequently washed twice and resuspended in 250 µl PBS containing 5µl 7-AAD for 
analysis. During acquisition of FACS data, the live cells (negative for 7-AAD) were 
gated and evaluated for ROS with CM-H2DCFDA. Further, the fluorescence intensity of 
CM-H2DCFDA was also gated uniformly to designate positive events of CM-H2DCFDA 
stained cells. The % gated for positive stained CM-H2DCFDA was used as the indicator 
for ROS levels in different treatment groups.  
 
5.2.5 Determination of intracellular GSH 
 
Cells seeded on 24-well plates were subjected to different experimental conditions. At the 
end of incubation, the cells were washed twice with PBS and the harvested cells were 
lysed using lysis buffer (20mM HEPES, 1mM EGTA, 210mMmannitol and 70mM 
sucrose, pH7.2). Intracellular GSH was analyzed by Glutathione Assay Kit from Cayman 
Chemical. Total protein levels were analyzed by Quick Start Bradford Protein Assay Kit 
from Bio-Rad. All manufacture’s protocols were followed. Total GSH levels in each 
group were normalized to total protein levels to obtain GSH concentrations in µg/mg. 
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GSH levels in cells incubated with culture medium served as control and were used to 
normalize across different groups. 
 
5.2.6 Mitochondrial inner membrane potential 
 
Mitochondrial inner membrane potential was measured by JC-1 (Mitochondrial 
Membrane Potential Assay Kit) according to manufacturer’s protocol and measured by 
both fluorescence microplate reader SpectraMax from Molecular Devices (CA, USA) and 
fluorescence microscope Zeiss Axiovert 200M(Germany). (J- aggregates (red): 
excitation/emission= 560/595nm; JC-1 monomers(green): excitation/emission= 
485/535nm) 
 
Following treatments, digital images were taken by an inverted fluorescence microscope 
fitted with a matched Axiocam 4 mega-pixel camera. Images were captured using 20× 
objective lens (N.A. 0.3) to characterize the JC-1 monomers inside the mitochondria.  
In addition, fluorescence microplate reader was also used to quantify the J-aggregates as 
well as JC-1 monomers in 96-well cell culture plates following treatments. The 
fluorescence ratio of JC-1 aggregates and JC-1 monomers was calculated for each well.  
 
5.2.7 Mitochondrial superoxide levels  
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MitoSOX red reagent was used to quantify superoxide anion produced from 
mitochondria. MitoSOX permeates live-cells, target to mitochondria and exhibit red 
fluorescence once oxidized by superoxide. MitoSOX stained cells were measured by 
fluorescence microscopy.  
 
Following treatments, digital images were taken by an inverted fluorescence microscope 
(Zeiss Axiovert 200M) fitted with a matched Axiocam 4 mega-pixel camera. Images 
were captured using 20× objective lens (N.A. 0.3). The excitation/emission spectra for 
MitoSOX were set up at 510/580nm as manufacture’s protocol. 
 
5.2.8 Mitochondrial GSH (mtGSH) levels 
 
Mitochondria were isolated using Mitochondria Isolation Kit for Cultured Cells following 
experimental treatments. Isolated mitochondria were further lysed with buffer (20mM 
HEPES, 1mM EGTA, 210mMmannitol and 70mM sucrose, pH7.2). Subsequently 
mtGSH levels were measured using GSH assay kit the same way as the determination of 
the intracellular GSH. Total protein levels were measured and acquired mtGSH levels 
were expressed in µg/mg total protein. mtGSH levels in cells treated with culture medium 
served as control and were used to normalize across different groups. 
 
5.2.9 ATP production analysis 
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ATPlite™ Luminescence Assay System was used to detect ATP production as per 
manufacturer’s protocol on 24-well cell culture plates post experimental treatments. 
 
5.2.10 Statistical analysis 
 
For all cellular assays, results were expressed as means ± standard error. Data was 
analyzed using ANOVA with a Bonferroni’s correction for multiple comparisons or 
Dunnett’s test in case of performing multiple comparisons towards the control. A p-value 
<0.05 was considered significant. Analyses are based on data from three independent 
experiments using different cell passages on different days. 
 
5.3 Results 
 
5.3.1 VLCFAs reduce cell survival and ATP production 
 
Murine oligodendrocyte cells (158N) were exposed to increasing concentrations of 
hexacosanoic acids (C26:0) (range from 1-100 µM) for a period of 24hrs. Ethanol treated 
cells were used as vehicle control. Cell viability and intracellular ATP production were 
measured following C26:0 treatments. The survival of oligodendrocytes was not 
significantly influenced by incubation with C26:0 at concentrations less than 25µM 
(Figure 5-1 A). However, the cell survival rates were significantly lower at 25µM 
(84±3%) and 50 µM (60±8%) C26:0, compared to vehicle control (Dunnett’s test, 
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p<0.01). Moreover, we observed a concentration- dependent decrease in ATP production 
following treatment with C26:0 (Figure 5-1 B), suggesting there might be potential 
toxicity of VLCFAs on mitochondria where most of the ATP is produced.  The 
concentration of C26:0 at 25µM seemed to be quite interesting in that though cell death at 
this concentration was ~15%, ATP production was found to be significantly lower 
compared to vehicle controls (Dunnett’s test, p< 0.05). Combined together, the lower 
toxicity limit was found to be 25 µM for C26:0 on both cell survival and ATP production.  
 
 
Figure 5-1 C26:0 reduced cell survival (A) and ATP production (B) in a concentration 
dependent manner. A) Percentage of viable 158N cells after incubation with C26:0 (0-
100 µM) for 24 hrs are shown (Fig 1A, n=6). At concentrations of C26:0 equal to and 
higher than 25 µM, significant cell death was observed, ** p<0.01, ANOVA followed by 
Dunnett’s test. 1% and 2% ethanol were both used as control and no difference was 
observed between controls (data not shown). B) ATP production was also evaluated after 
incubation with C26:0 (0-50 µM) for 24 hrs (Fig 1B, n=6). At concentrations of C26:0 
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equal to and higher than 25 µM, significant decrease in ATP production compared to 
ethanol control was observed, *p<0.05, ** p<0.01, ANOVA followed by Dunnett’s test. 
 
5.3.2 VLCFAs do not cause significant changes in cellular oxidative stress  
 
In order to evaluate the effect of VLCFAs on oxidative stress, we analyzed ROS (as 
measured by H2DCFDA) and intracellular GSH (total) levels in oligodendrocytes 
following treatment with C26:0 at the threshold concentration 25 µM for 24 hrs. 
Although the trend of increased ROS formation was observed, the increase was not 
significant compared to vehicle treated controls (Figure 5-2, t test, p=0.17). Importantly, 
25 µM C26:0 did not cause any depletion in total GSH (Figure 5-3 A, t test, p=0.99) as 
compared to vehicle controls. 
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Figure 5-2 ROS levels in 158N cells after incubation with C26:0 and NAC for 24 hrs 
were measured (n=3) and 25µM C26:0 did not change cellular ROS levels as measured 
by H2DCFDA. No statistical significance was observed between ethanol control and 25 
µM C26:0 treatment (t test, p =0.17). Additional co-incubation of NAC (100-1000 µM) 
did not change cellualr ROS levels either. 
 
5.3.3 VLCFAs deplete mtGSH, affect mitochondrial redox balance and induce 
mitochondrial depolarization   
 
Although low levels of VLCFAs did not affect the cellular oxidative stress, there was 
~16% cell death and ~23% decrease of ATP production on exposure to 25 µM C26:0 for 
24 hrs. To further understand how C26:0 exerts its toxicity on cells, several key 
parameters describing mitochondrial redox status and function were measured including 
levels of mtGSH, superoxide anions and mitochondrial inner membrane potential (ΔΨm).   
Interestingly, although VLCFAs did not cause any depletion in total GSH (Figure 5-3 A, t 
test, p=0.99), we observed a significant depletion to ~0.2 fold of control in the levels of 
mtGSH (Figure 5-3 B, t test, p<0.01), indicating that VLCFAs have a major influence on 
the mitochondrial antioxidant defense system. This observation of depletion in mtGSH 
without any change in total GSH may also indicate possible translocation of intracellular 
total GSH from mitochondria to cytosol induced by C26:0 treatments. 
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Figure 5-3 Total intracellualr GSH (A) and mtGSH levels (B) in 158N cells were 
measured after incubation with C26:0 and NAC for 24 hrs (n=3).  A) No statistical 
significance in total GSH was observed between control and C26:0 (25µM) (t test, 
p=0.99). Additional co-incubation of NAC (100-1000 µM) increased total GSH in a 
concentration dependent manner (A; ***p<0.001, ANOVA followed by Dunnett’s test); 
B) Significant decrease in mtGSH was observed between control and C26:0 (25µM) (t 
test, p <0.01). Additional co-incubation of NAC (500 µM) restored mtGSH depleted by 
C26:0 (B; ***p<0.001 indicates significant increase in mtGSH with co-incubation of 
NAC compared to C26:0(25µM) treatment only; ANOVA followed by Bonferroni test). 
Moreover, mtGSH was increased to 2.2±0.1 fold of control when performing pre-
treatment with C26:0 (25µM) for 18hrs followed by NAC (500 µM) only for 6hrs. 1% 
Ethanol treated cells served as control. 
 
Next we proceeded to examine the influence of C26:0 treatments on levels of superoxide 
anion. Superoxide anion (O2
-
) is produced mainly in mitochondria as the first free radical 
to drive further ROS production in mitochondria (Kirkinezos and Moraes, 2001). 
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MitoSOX red reagent that specifically target mitochondria was used to quantify 
superoxide anion. As shown in Figure 5-4, panel C, Treatment of 25 µM C26:0 for 24hrs 
greatly increased the superoxide anion levels as shown by the excited MitoSOX 
fluorescence (red). Solvent (1% ethanol) does not affect the mitoSOX fluorescence (data 
not shown). A concentration-dependent toxicity of C26:0 was also observed (Figure 5-4, 
panel B to C). These results indicate that VLCFAs increased the superoxide anion levels 
within mitochondria; however, the increase could be due to either accelerated superoxide 
anion production or impaired antioxidant defense system. 
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Figure 5-4 C26:0 increased mitochondrial superoxide levels and NAC decreased the 
levels. Representative images of 158N cells showing increase in MitoSOX fluorescence 
(red) following treatment with C26:0 (0-25µM) for 24 hrs. Additional co-incubation of 
NAC (500 µM) notably decreased MitoSOX fluorescence indicating decreased levels of 
mitochondrial superoxide formation. No difference in MitoSOX fluorescence was 
observed bwtween vehicle control (1% Ethanol) and media control (data not 
shown).Scale bars represent 50 µm.  
 
To further characterize toxic effects of C26:0 on mitochondrial function, we measured 
another crucial parameter, mitochondrial inner membrane potential. JC-1 is a lipophilic 
fluorescent dye that acts as the mitochondrial inner membrane potential (ΔΨm) indicator. 
In healthy cells with high ΔΨm, JC-1 spontaneously formed J-aggregates with red 
fluorescence while in unhealthy cells with low ΔΨm, JC-1 remained in the monomeric 
form with green fluorescence. We monitored the green monomeric JC-1 dye specifically 
for tracking the unhealthy cells with low ΔΨm by fluorescence microscopy. We observed 
that percentage of low ΔΨm cells increased in a concentration-dependent fashion with 
increasing C26:0 (Fig 5-5, panel A to D). Accordingly, when we measured the ratio of 
healthy and unhealthy cells by fluorescent plate reader, we also observed decrease in the 
ΔΨm (Fig 5-6). These results indicate that VLCFAs adversely affect the mitochondrial 
inner membrane potential.  
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Figure 5-5 C26:0 decreased mitochondrial inner membrane potential (ΔΨm) and NAC 
alleviated this effect. A): Representative images of 158N cells showing increase in JC-1 
monomers (green fluorescence in dead cells) following C26:0 (0-50 µM) incubation for 
24 hrs. Additional co-incubation of NAC decreased green fluorescence, indicating 
restoration of ΔΨm. Scale bars represent 50 µm. 
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Figure 5-6 Bar plot indicated quantification of JC-1 fluorescence in 96-well plates. The 
ΔΨm decreased significantly following incubation with C26:0 (25µM and 50µM) 
compared to control (p<0.001, ANOVA followed by Dunnett’s test). This mitochondrial 
toxicity was reversed by NAC (# p<0.05, ANOVA followed by Bonferroni test). 
 
5.3.4 Effect of NAC treatment on VLCFA induced mitochondrial toxicity 
 
We were interested to examine whether the mitochondrial specific effects of VLCFAs 
can be reversed by treatment with NAC. For this we co-incubated158N oligodendrocytes 
with 500µM NAC and 25 µM C26:0 for 24 hrs and performed similar analysis as 
mentioned in previous section. 
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NAC replenishes mtGSH  
 
We analyzed both intracellular total GSH and mtGSH levels in 158N oligodendrocytes 
incubated with C26:0 (25 µM) and NAC (500 µM). We observed that NAC was able to 
replenish the mtGSH levels back to normal levels during co-incubation while 
intracellular total GSH was observed to increase simultaneously (Figure 5-3, A and B). In 
particular, pretreatment with C26:0 (25µM, 18hrs) followed by NAC (500µM, 6hrs) was 
found to induce the mtGSH levels to 2.2±0.1 fold of control, indicating NAC as a potent 
antioxidant to replenish mtGSH during depletion (Figure 5-3 B). These results suggest 
that replenishment of mtGSH is one potential mechanism by which NAC provides 
cellular protection.  
 
NAC Reverses C26:0 Induced Increase in Mitochondrial Superoxide  
 
In a parallel set of experiments, we evaluated the levels of superoxide anions within 
mitochondria after the co-incubation of NAC and C26:0 (Figure 5-4, panel C to D). 
C26:0 increased mitochondrial superoxide formation in oligodendrocytes in a 
concentration-dependent manner and addition of 500 µM NAC notably decreased 
MitoSOX fluorescence. Results indicate that treatment with NAC could effectively 
decrease superoxide anion levels in mitochondria. 
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NAC Alleviates C26:0 Induced Decrease in Mitochondrial Inner Membrane Potential 
(ΔΨm) 
 
Previously, we observed C26:0 induced mitochondrial depolarization in 158N cells. The 
percentage of unhealthy cells increased (Figure 5-5, panel A to D) and mitochondrial 
inner membrane potential (ΔΨm) decreased (Figure 5-6). Subsequently, we evaluated the 
therapeutic effects of NAC in cells incubated with C26:0. Surprisingly, 500 µM NAC 
was shown to effectively decrease the percentage of unhealthy cells (Figure 5-5, panel E), 
as well as increase ΔΨm (Figure 5-6). These results indicate that NAC could reverse the 
toxic effect of VLCFAs on mitochondrial inner membrane potential.  
 
5.3.5 VLCFAs Increase the Sensitivity to Chemical Oxidants in 158N 
Oligodendrocytes 
 
Although C26:0 at threshold toxicity concentration (25 µM) was observed to deplete 
mtGSH, increase levels of superoxide anions, as well as impair mitochondrial inner 
membrane potential, it did not demonstrate any significant effects on intracellular ROS 
and total GSH levels, causing moderate cell death. We hypothesized that the induced 
mitochondrial toxicity by pre-treatment of C26:0 would sensitize the cells towards death 
when encountering further chemical oxidants. Acrolein, the major reactive oxidant 
metabolite for the commonly used chemotherapeutic agent cyclophosphamide, was used 
to induce further oxidative stress to the cells. We then measured cell viability following 
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incubation with either threshold concentration of C26:0 or acrolein or both. 
Oligodendrocytes incubated with low concentrations of C26:0 (25µM, 24hrs) or acrolein 
(25µM, 1hr) showed modest cell toxicity (84±1% and 81±1% cell survival respectively). 
However, pre-treatment with C26:0 and subsequent incubation with acrolein at the same 
conditions profoundly showed cell toxicity (56±1.5% cell survival), indicating a 
synergistic cytotoxic effect (Figure 5-7). Results verified the hypothesis that pre-
treatment of C26:0 could increase the sensitivity to acrolein.  
 
Next we evaluated the effects of NAC in protecting C26:0 treated cells from additional 
acrolein treatment. NAC at 500 µM was co-incubated with C26:0 for 24hrs before 
replacing with acrolein for 1hr. As a result, we found that addition of NAC increased the 
cell survival to 71±3%, presumably by its effect on replenishing mtGSH thereby 
desensitizing the cells to acrolein. 
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Figure 5-7  C26:0 increased sensitivity to acrolein in 158N cells. Cell survival rates 
following treatments with C26 only (25 µM, 24hrs), acrolein only (25µM, 1hr), C26 (25 
µM, 24hrs) and then acrolein (25µM, 1hr), as well as C26 (25 µM)-NAC (500 µM) co-
incubation for 24 hrs and then acrolein (25µM, 1hr).  Pre-treatment with C26:0 and 
subsequent incubation with acrolein at the same conditions profoundly decreased cell 
survival (56±1.5%) compared to C26:0 or acrolein treatment. Addition of NAC in pre-
treatment procedure increased the cell survival to 71±3%, ** p<0.01, ANOVA followed 
by Bonferroni test. 
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5.4 Discussion 
 
Increased levels of VLCFAs in plasma and tissues and mutations in Abcd1 gene are 
hallmarks of ALD. Mutated Abcd1 gene causes impaired degradation of VLCFAs which 
come from either endogenous synthesis by microsomal elongation system or exogenous 
source of diet (Moser et al., 2005a). However, the detailed pathology regarding to how 
accumulation of VLCFAs leads to neurodegeneration in CCALD is still unclear. In vitro 
toxicity assays using VLCFAs such as C26:0 offer great insights into the pathology of 
ALD. Previous studies have investigated the toxicology of VLCFAs on fibroblasts from 
ALD patients (Fourcade et al., 2008, Fourcade et al., 2010, Galino et al., 2011), on rat 
hippocampal cell cultures of oligodendrocytes and astrocytes (Hein et al., 2008), as well 
as on established oligodendrocyte cell lines (Baarine et al., 2012a, Baarine et al., 2012b). 
 
VLCFAs were found to impact total intracellular GSH levels and cell survival (Fourcade 
et al., 2008), reactive oxygen species (ROS) and nitrogen species (RNS) production 
(Baarine et al., 2012a), as well as mitochondrial and lysosomal functions (Baarine et al., 
2012b) in vitro. A wide range of concentrations (1- 100 µM) of VLCFAs were 
investigated. Interestingly, there seemed to be a threshold level where VLCFAs induce 
detrimental toxicity in oligodendrocytes. At concentrations lower than the threshold, cell 
viability was minimally affected while elevated concentrations of VLCFAs decreased cell 
survival profoundly. Notably, the threshold concentrations of VLCFAs were within the 
range of reported values in plasma and tissue concentrations of ALD patients (Baarine et 
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al., 2012b). Thus VLCFAs might dispose the cells towards oxidative stress without 
affecting cell viability, becoming the first hit in the “three-hit hypothesis” (Singh and 
Pujol, 2010). Three-hit hypothesis assumed oxidative stress as the first hit in ALD 
disease pathology. Subsequently a second hit of inflammation or other stressors would 
then lead to loss of cell function and cell death as the final hit. The three hit hypothesis 
was quite helpful to explain the finding that the plasma concentrations of VLCFAs does 
not correlate with the disease severity or age of onset (Ofman et al., 2010) since a second 
hit is required for disease progression. We were interested to examine the effect of this 
“first hit” using threshold concentration of C26:0 in vitro. 
 
Oxidative stress resulting from accumulation of VLCFAs was thought to highly associate 
with ALD disease progression (Powers et al., 2005). Evidence of oxidative stress as a 
hallmark of ALD has been shown in recent studies (Vargas et al., 2004, Fourcade et al., 
2008) . Vargas et al., evaluated oxidative stress biomarkers in plasma, erythrocytes and 
fibroblasts from ALD patients. Results showed that biomarkers indicating free radicals 
and lipid peroxidation were elevated in ALD patients compared to control while total 
antioxidant capacity was decreased indicating a deficient capacity to rapidly handle 
oxidative stress (Vargas et al., 2004). Additionally, in Abcd1- murine models increased 
reactive oxygen species (ROS) formation and elevation of other oxidative stress markers 
were observed early on in disease progression (Fourcade et al., 2008).  
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As 95% of ROS is produced through the mitochondrial respiratory chain as byproducts of 
O2 consumption and ATP generation (Emerit et al., 2004), oxidative stress is highly 
associated with mitochondrial function. It has been discussed widely whether VLCFAs 
could lead to mitochondrial dysfunction or not. And if it is true, the pathogenic pathways 
remain to be identified. Mitochondrial abnormalities and impaired cross-talk between 
mitochondria and peroxisome were observed in human and mouse Abcd1- fibroblast cells 
(McGuinness et al., 2003). Impaired mitochondrial oxidative phosphorylation and 
increased mtDNA oxidation was also observed in ALD patients' fibroblasts and Abcd1- 
mouse models (Lopez-Erauskin et al., 2013). Further, VLCFA affected the mitochondrial 
inner membrane potential, and was a likely mechanism for “mitochondrial-based cell 
death” (Hein et al., 2008). However, one report showed that mitochondrial abnormalities 
had no relationship with accumulation of VLCFAs based on Abcd1-mouse model and 
ALD patients’ fibroblast cells (Oezen et al., 2005).  
 
In our study, we were interested to investigate whether VLCFAs have any impact on 
mitochondrial function. Interestingly, we were able to show consistent results with 
previous publications that VLCFAs could cause decrease in ATP production and inner 
membrane potential, as well as increase in the superoxide species within mitochondria. 
Moreover, we were able to identify a new pathogenic effect of VLCFAs that it 
specifically depleted the mtGSH. In CCALD disorders with accumulation of VLCFAs, 
depletion of mtGSH could possibly cause mitochondria dysfunction and trigger further 
oxidative stress cascade. The imbalance between ROS and antioxidants within the 
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mitochondria might be one of the crucial pathways leading to mitochondrial dysfunction 
and can be the first hit on neurodegeneration. 
 
To examine whether this pathogenic mechanism can be targeted, we performed 
experiments with NAC, which can potentially replenish the mtGSH depleted by VLCFAs. 
NAC is a precursor of cysteine, which is the rate-limiting endogenous substrate for 
generation of GSH, the crucial antioxidant in cells that protects against damage from free 
radicals. mtGSH has emerged as the major defense mechanism to maintain mitochondrial 
function (Mari et al., 2009). We were interested to know whether NAC could replenish 
the mtGSH levels which should be able to relieve the first hit of oxidative stress. With 
that in mind, we co-incubated NAC with VLCFAs to examine mitochondrial function 
parameters. Interestingly, NAC has an effect on reversing mitochondrial dysfunction 
caused by VLCFA accumulation. 
 
The fact that pre-treatment with VLCFAs could increase the sensitivity to chemical 
oxidants further verified our hypothesis of first hit stress by VLCFAs (Figure 5-8). 
Depletion of mtGSH was thought to be the cause for increased sensitivity. In the disease 
pathology of CCALD, accumulation of VLCFAs could possibly increase the sensitivity 
of cells towards exogenous oxidative stimuli, pre-disposing the cells towards oxidative 
stress and resulting in irreversible cell death. NAC pre-treatment along with VLCFAs 
could replenish mitochondrial GSH thus sabotage the hypersensitivity.  In our 
experiments, NAC has been shown to be a potential therapeutic agent in normalizing the 
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redox status in mitochondria. Also, these studies may lead to future clinical approaches 
wherein NAC can be combined with mitochondrial cofactors (Vitamin C, Vitamin E and 
Coenzyme Q) to enhance its therapeutic benefits. 
 
 
 
Figure 5-8 Figure shows hypothesized model depicting first hit by C26:0 which depletes 
mtGSH. And loss of mtGSH subsequently pre-disposes the cells towards death in 
encountering additional stress such as oxidants. NAC reverses the mitochondrial toxicity 
of C26:0 by replenishing mtGSH, and thus protects against future oxidative insult. Figure 
adapted from (Mari et al., 2009). 
 
5.5 Conclusion 
 
Accumulation of VLCFAs (C26:0) has been implicated in oxidative stress and 
consequent neurodegeneration [1]. The myelin-producing oligodendrocytes are 
particularly sensitive to VLCFAs. To further understand the toxic effects of VLCFAs, we 
exposed oligodendrocytes to hexacosanoic acid (C26:0) and analyzed cellular responses. 
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We observed significant mitochondrial toxicity of VLCFAs contributing to sensitivity 
towards further oxidative stimuli. We then examined if these mitochondria-specific 
effects of VLCFAs are reversed using antioxidants. We evaluated the effect of a well-
known antioxidant NAC on the toxicity induced by VLCFAs in oligodendrocytes. Our 
data indicate that NAC has an effect on reversing mitochondrial dysfunction caused by 
VLCFAs accumulation, which is commonly observed in neurodegenerative diseases 
associated with peroxisomal defects. 
 
Our future studies will target at further characterizing the precise mechanisms of NAC in 
restoring mitochondrial function and use various combinations of antioxidants to 
optimize and maximize the protective effects on mitochondria. 
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CHAPTER 6 
A PHARMACOKINETIC AND PHARMACODYNAMIC 
STUDY OF N-ACETYLCYSTEINE TO UNDERSTAND ITS 
EFFECT ON BRAIN AND BLOOD GLUTATHIONE 
STATUS IN WILD-TYPE MICE 
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6.1 Introduction 
 
NAC is a well-known antioxidant, indicated for mucolysis in cystic fibrosis and other 
respiratory conditions and as an antidote for acetaminophen overdose (Heard and Green, 
2012a, Rushworth and Megson, 2013b). Recently, NAC has gained renewed attention as 
a potential therapy for a number of conditions including neurological(Adair et al., 2001, 
Berman et al., 2011), cardiac injury (Mahmoud and Ammar, 2011),  metabolic (Badaloo 
et al., 2002, Atkuri et al., 2007) and HIV infection (De Rosa et al., 2000), due in part to 
its antioxidant properties as well as the capacity to replenish glutathione (GSH) levels.  
 
GSH is a potent endogenous antioxidant which scavenges free radicals non-enzymatically. 
The depletion of GSH is often used as an indicator for oxidative stress (Wu et al., 2004b). 
For example, lower levels of GSH was found in brain of patients with multiple sclerosis 
(Choi et al., 2011a) and impaired GSH metabolism and imbalance is linked to 
Parkinson’s disease (Zhou and Freed, 2005a, Choi et al., 2006a), Alzheimer’s 
disease(Lovell et al., 1998), X-Aldrenoleukodystrophy (X-ALD) (Petrillo et al., 2013b) 
and Gaucher’s disease (Roversi et al., 2006). The ratio of the reduced form (GSH) and 
oxidized form (GSSG) is defined as the redox ratio, which is used as another indicator for 
oxidative stress (Nemeth and Boda, 1994). Decreased redox ratios were reported to be 
associated with diabetes, autism in children and cancer (James et al., 2004, Bravi et al., 
2006, Chauhan et al., 2012, Zitka et al., 2012).  
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NAC is widely investigated in conditions where GSH depletion and abnormal redox 
ratios are involved (De Rosa et al., 2000, Al-Tonbary et al., 2009, Dean et al., 2011b). 
Our research group showed that high doses of intravenous NAC can increase both blood 
and brain GSH levels in humans. In addition, this increase in GSH by administration of 
NAC is not only observed in patients with Parkinson’s and Gaucher’s disease, but also in 
healthy subjects who are assumed to have normal GSH levels (Holmay, et al. 2013). 
However, this study is lack of scientific rationale for dose selection. Moreover, high-dose 
intravenous administration is not likely feasible as long-term therapy. Quantitatively 
characterizing the relationship between NAC dosing and increased GSH levels/redox 
ratios is thus necessary and crucial for selection of dose, regimen, and route of 
administration. 
 
NAC has long been considered to contribute to the maintenance of intracellular GSH 
levels by providing the rate-limiting substrate cysteine for GSH synthesis(van Zandwijk, 
1995b). However, the precise mechanism by which this occurs is not well understood. 
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Figure 6-1 Structure of stable-labeled 15N-Acetyl(13C3) L-Cysteine, isotope atoms were 
shown with asterisk(*); Biotransformation pathways of NAC into GSH. Pathway A: 
cysteine is formed through deacetylation by acyclase I to form cysteine, and further used 
for GSH synthesis. Pathway B: NAC exchanges thiol with oxidized form of cysteine and 
releases free reduced form cysteine for GSH synthesis. Pathway C: NAC directly 
exchanges thiol with oxidized form of GSH and releases free reduced form GSH. In 
pathway A, the final product GSH carries the stable labels from labeled NAC but both 
pathway B and C do not carry the label.   
 
NAC was reported to increase GSH levels by direct deacetylation to cysteine  (Fig1, 
pathway A)(Nakagawa et al., 2013) or by indirectly modulating cysteine/GSH levels 
through thiol exchange (Fig1, pathway B&C)(Ventura et al., 1999, Raftos et al., 2007, 
Whillier et al., 2009, Radtke et al., 2012). Stable isotope labeled NAC (15N-Acetyl (13C3) 
L-Cysteine) was used in this study to differentiate exogenous source for synthesis 
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(labeled) from endogenous source of GSH (non-labeled), (Fig 1). In pathway A where 
deacetylated NAC contributes to the synthesis of GSH, GSH would also carry the stable 
labeled atoms, whereas in pathway B&C where NAC makes endogenous cysteine or 
GSH available, the final product GSH will not have isotope atoms. Mass spectrometry 
analysis can be used to differentiate the endogenous (non-labeled) GSH and exogenous 
(labeled) GSH based on their differences in molecular weight.  
 
The objective of this study was to examine the biotransformation and disposition of NAC 
in blood and brain of mice following an intravenous dose of a stable-labeled NAC 
solution. Moreover, the therapeutic potential of NAC to increase GSH levels in 
RBCs/redox ratios in brains was also evaluated and PK/PD relationships between NAC 
concentrations and GSH concentration increases in RBCs developed.  
 
6.2 Materials and Methods: 
 
6.2.1 Materials 
 
Phosphate buffered saline (PBS) was obtained from Life Technologies (CA, USA). 
Unlabeled NAC and glutathione (GSH) used as calibration standards were purchased 
from Sigma-Aldrich (MO, USA). 1M Dithioerythritol (DTE) solution in water was 
obtained from Sigma-Aldrich (MO, USA). 
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6.2.2 Subjects 
 
Experimentally naïve, 12-week-old female C57BL/6NCr mice were obtained from 
National Cancer Institute (MD, USA). Mice were housed in rooms with a 12:12 
light/dark cycle at 21.1-22.8 °C with water and food. Mice were acclimated in the UMN-
TC facility for a minimum of one week.  
 
All experiments were conducted under the approval of University of Minnesota 
Institutional Animal Care and Use Committee (IACUC). 
 
6.2.3 NAC intravenous formulation 
 
Stable isotope-labeled NAC (15N-Acetyl 13C3 L-Cysteine) was purchased from 
Cambridge isotope laboratories (Andover, MA).  During manufacturing of the labeled 
NAC, three carbon-12s and one nitrogen-14 in the cysteine group were replaced with one 
carbon-13 each and with one nitrogen-15, respectively resulting in a compound with 4 
mass units greater than the unlabeled NAC. Representative spectra of this compound are 
shown in Figure 6-2. 
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Figure 6-2 LC/MS chromatography of stable-labeled NAC (A , B) and unlabeled NAC (C, 
D). Isotope atoms were labeled on the cysteine group of the NAC molecule, resulting in 
increase of 4 mass units in molecular weight (m/z=168, positive mode, B) as shown on 
Mass Spectrometry (MS) compared to non-labeled NAC (m/z=164, positive mode, D), 
while peaking at the same location (approximately 5.0 min) as unlabeled NAC on liquid 
chromatography (HPLC) graph (A, C). 
 
Stable-labeled NAC was dissolved in PBS at a concentration of 28g/L. Then the solution 
was adjusted to pH 7.0 and passed through a 220nm syringe filter on the day of 
experiment. 
 
6.2.4 Drug administration 
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A single NAC dose of 150mg/kg was administered intravenously in the tail vein of each 
mouse. Sterile PBS solution was also prepared and administered to the mice assigned to 
the baseline group. 
 
6.2.5 Sampling methods 
 
A destructive sampling method was employed. 22 mice were randomized to 7 groups. At 
baseline (dosed with saline), 5min, 15min, 30min, 60min, 90min, and 150min post-
dosing, one group of mice was anesthetized using carbon dioxide. Blood samples were 
collected using cardiac puncture afterwards at each specified time point. Whole blood 
was placed in tubes pre-treated with heparin. Fresh whole blood was centrifuged 
immediately at 1500g for 5 minutes to separate plasma and RBCs. Upper layer plasma 
and lower layer RBCs were immediately snap frozen in liquid nitrogen and subsequently 
stored at -80 °C for further analysis of NAC and its metabolites. Whole brain tissues were 
perfused with pre-heated PBS to clean blood, and subsequently snapped frozen in liquid 
nitrogen and stored at -80 °C, and weighed afterwards for further analysis. 
 
6.2.6 Plasma/RBC/brain sample processing methods 
 
In order to measure the total concentrations of NAC and GSH including both reduced and 
oxidized forms, plasma and RBCs were co-incubated with 1:2 volume ratio of 0.5mg/ml 
the reducing agent dithioerythritol (DTE) at 37 
o
C for 30minutes prior to analysis. Brain 
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tissue homogenates were prepared without reducing agent to measure both GSH and 
GSSG levels for redox ratio calculation. Bullet Blender storm from Next Advance (NY, 
USA) was used for brain tissue homogenization according to manufacturer’s protocol 
under 4
o
 C.  
 
6.2.7 Analytical methods 
 
Total NAC concentrations in plasma, total GSH levels in RBCs and GSH/GSSG redox 
ratios in brain tissue homogenates were analyzed using liquid chromatography-mass 
spectrometry (HPLC-MS) (Agilent Technologies, CA, USA) with  series 1100 system 
consisted of a G1322A degasser, a G1311A quaternary pump, and a G1313A 
autosampler. The electrospray interface is connected to a single quadrupole G1946A.  
The HPLC-MS system was controlled and data were processed using Chemstation 
software (Agilent Technologies, CA, USA).   
 
Briefly, processed RBC and brain tissue samples were mixed with equal volume of RBC 
lysis solution (Qiagen, MD, USA) and gently votexed. 2 ml of methanol was added into 
100 µL of obtained brain lysates/RBC lysates/plasma prior to vortexing. After 
centrifuging at 2500 rpm for 10 minutes at 4°C, the organic supernatant was transferred 
into glass tubes and evaporated under nitrogen gas at 37°C. Dried samples were 
reconstituted with mobile phase and filtered into HPLC vials using nylon acrodisc 
syringe filters (Pall Life Sciences, MI, USA). Separation of compounds was performed 
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using mobile phase consisting of 98% 20mM ammonium formate buffer (pH 3.0) and 2% 
acetonitrile through Agilent ZORBAX Eclipse XDB-C18 (3×150mm, 3.5µm) column. 
The flow rate was 0.35 ml and the total analytical period for each sample was 10 minutes. 
Finally, samples were analyzed using selective ion monitoring (SIM) mode, detecting 
positive ions for labeled NAC (m/z, 168), unlabeled GSH (m/z, 308), labeled GSH (m/z, 
312) and oxidized GSSG (m/z, 614). 
 
Calibration standards were prepared in plasma, red blood cells, and brain and analyzed 
with the corresponding samples.  NAC calibration standards (1-200 µg/ml) were prepared 
daily and spiked into mouse plasma. Quality control NAC standard in plasma was also 
prepared with a final NAC concentration of 10ug/mL to run with every batch of samples. 
GSH calibration standards (250-1000 µg/ml) were prepared and spiked into RBC lysates 
from control mice. Quality control GSH standard in RBC lysates was prepared with a 
final GSH concentration of 500 µg/ml. GSH standards (1.25-50 µg/ml) and GSSG 
standards (1.25-50 µg/ml) were prepared and spiked into brain tissues homogenates from 
control mice. Quality controls were prepared at 10µg/ml for both GSH and GSSG in 
brain homogenates. All samples and standards were analyzed in duplicates.  
 
The lower limit of quantitation (LLOQ) of the assay was 1µg/mL for NAC and 0.625 
µg/mL for both GSH and GSSG. The average within-run precision was 5.0% for NAC in 
plasma.  The between-run precision was 8.4% for NAC in plasma. The recovery rates for 
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GSH and GSSG in red blood cells and brain tissues were between 91% and 97% for 
standards ranging from 1.25 to 1000 µg/ml.  
 
6.2.8 Treatment of NAC Plasma Concentrations below the Limit of 
Quantification (BLQ) 
 
The rules for treating the reported NAC plasma concentrations below the BLQ were pre-
defined as missing since there was only one sample per subject in destructive sampling. 
 
6.2.9 Non-compartmental PK analysis 
 
Area-under-the-curve (AUC), maximum concentration (Cmax), elimination half-life (t1/2), 
clearance (CL) and Volume of distribution (Vd) were estimated in Phoenix WinNonlin 
(Version6.3, Pharsight Corp., NC,USA) using non-compartmental analysis (NCA) of 
sparse sampling method (Nedelman and Jia, 1998). In addition, two bootstrapping re-
sampling methods (Mager and Goller, 1998), Pseudoprofile-based bootstrap (PpbB) and 
Pooled data bootstrap(PDB), designed specifically for destructive sampling, were also 
performed in R software (version 3.0.1, open source). PK analysis results were compared 
between the three different methods. 
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Area under the curve above baseline (AUCb) for unlabeled and labeled GSH was 
estimated in Phoenix WinNonlin (Version6.3, Pharsight Corp., NC, USA) by linear 
trapezoidal linear interpolation rule.  
 
6.2.10 Population pharmacokinetic/pharmacodynamic analysis 
 
Due to the nature of destructive sampling procedures, each animal contributed to only 
one data point. Thus, it is not possible to evaluate the inter-individual variability and 
residual random variability due to identifiability issues. Therefore, residual random 
variability in population PK analysis and population PK/PD analysis was fixed to reflect 
the magnitude of assay errors. 
 
Compartmental population PK analysis was performed via nonlinear mixed effects 
modeling in Phoenix NLME (version 1.2, Pharsight Corp., NC, USA) using the first-
order conditional estimation method with interaction.  
 
An exponential variance model was used to describe the inter-individual variability of PK 
parameters:  
 
Pi =TVP*EXP(ηi),  
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where Pi is the estimated parameter for the i
th 
individual, TVP is the typical population 
mean of the parameter, and ηi is the deviation from population mean TVP for ith 
individual, which is assumed to be distributed: η~N(0, ω2). A two compartmental model 
was found to be the best-fit based on pre-defined goodness of fit criteria. Observed 
concentration Cobs was fitted into two-compartmental model where intra-individual 
variability (ηi) were modeled on volume (V1) and rate constants k12, k21 and k10 as 
shown in Figure 6-3.  
 
Proportional, additive, and combined additive and proportional residual error models 
were investigated during the model selection. In the final model, residual error was 
described by exponential error model:  
 
Cobsij =Cij*EXP(εij), 
 
where Cobsij is the observed plasma concentration for i
th
 individual at j
th
 time point, Cij is 
the predicted concentration and εij is the exponential error term under the assumption that 
ε~ N(0, σ2), σ2 were fixed to 0.01 to resolve the identifiability issue. The differential 
equations for population PK modeling can be expressed as following with X(1) as the 
central compartment and X(2) as the peripheral compartment. 
 
dX(1)/dt = -K10*X(1) – K12*X(1)+ K21*X(2) 
dX(2)/dt = K12*X(1) – K21*X(2) 
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Models were selected based on following criteria: 1) successful minimization 2) visual 
goodness of fit of diagnostic plots and 3) precision of model parameters as measured by 
the percent standard error of the mean (RSE %) 4) decrease in objective function value (-
2 * log-likelihood) for nested models or Akaike Information Criterion (AIC) and Schwarz 
Criterion(SBC).  
 
Population PK/PD modeling were implemented using ADAPT5 (Biomedical Simulations 
Resource, USC, CA, USA) (D’Argenio, et al. 2009) and ADAPT5 Model Evaluation 
Graphical Toolkit (AMGET), an external package written in the open source R 
programming language (version 3.0.1) (Guiastrennec et al., 2013). Maximum likelihood 
solution via the expectation-maximization Algorithm (MLEM) program was selected in 
ADAPT5 to implement the PK/PD models. In the program run, the lognormal 
distribution option was selected for the model parameters. Finally, 3000 samples/EM 
iteration and 50 EM iterations were specified. AMGET package in R was used to 
generate diagnostic plots such as visual predictive check (VPC) based on ADAPT5 
outputs.  
 
PD models were established as a combination of indirect response model and Emax 
model as shown in Figure 6-3, where Kin is the rate of production of GSH in RBC, Kout 
is the first-order elimination rate constant of GSH in RBC. Plasma concentrations of 
NAC are assumed to correlate with Kin defined by Emax model. Similarly to population 
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PK models, the inter-individual variability of PK/PD parameters were defined using 
proportional variance model Pi =TVP+ TVP*(ηi), η~N(0, ω2). And proportional residual 
error models were defined as GSHobsij =GSHij + GSHij*(εij), ε~N(0, 0.01). In addition, 
functions describing the process were expressed as: 
GSH(t) = Kin*(1 + Emax*X(1)/V / (EC50+X(1)/V) ) - Kin/GSH(0)*GSH(t)  
GSHobsij =GSHij*EXP(εij)  
ε~ N(0, σ2) and σ2 =0.01 
 
 
Figure 6-3 Structure of the PK-PD model for NAC-GSH. Simultaneous PK and PD 
analysis strategy was employed with fixed previously derived population PK parameters 
(population means, variance and covariance matrix). 
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6.2.11 Model evaluation 
 
The predictive properties of the final model were evaluated by performing visual 
predictive check. 3000 individual Monte-Carlo simulation was implemented in Phoenix 
NLME or ADAPT5 based on model structure and final estimates. Medians and 95% 
confidence intervals for both simulated data and observed data were plotted. The 
performance of the model was assumed to be acceptable if the observed data were 
appropriately distributed within the 5% and 95% of the simulated data. 
 
6.3 Results 
 
6.3.1 Non-compartmental PK analysis of NAC in wild type (WT) mice 
 
A total number of 22 female 12-week-old C57 WT mice received one single intravenous 
bolus dose of 150mg/kg NAC. The weight of mice was measured prior to dosing and was 
20.5±1.2 g (±SD). The NAC plasma concentration time profile is shown in Figure 6-4. 
Non-compartmental analyses (NCA) were performed using three different methods: NCA 
sparse sampling, pseudoprofile-based bootstrap (PpbB) and Pooled data bootstrap (PDB). 
AUCinf (from time 0 to ∞), AUClast (from 0 to last measurable concentration), C0 
(concentration at time 0), CL (clearance), T1/2 (half-life), Vd (Volume of distribution) 
were also estimated and shown in Table 6-1 respectively. Estimated parameters were 
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quite consistent when calculated by the three different methods. For example, the T1/2 
was estimated to be 24.5 minutes in NCA sparse sampling, 22.9±1.2 minutes in PpbB, 
and 23.9 ±1.9 minutes in PDB. A half-life of 20-25 minutes indicates that NAC was 
eliminated rapidly in mice. In addition, CL and Vd were estimated to be 0.035ml/min/g 
and 1.22 ml/g respectively using NCA sparse sampling method. 
 
 
Figure 6-4 Plasma NAC concentration- time profile in WT mice after application of BLQ 
rules. Data represents the mean±standard error following 150mg/kg NAC intravenous 
administration.   
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Table 6-1 NAC PK parameters estimated by three different NCA methods in WT mice.  
 
6.3.2 Compartmental population analysis of NAC in WT mice 
 
Population PK analysis was also performed to characterize the disposition of NAC in 
plasma. A 2-compartmental model (intravenous bolus dose) was selected as the best fit 
model according to previous defined criteria and parameterized with elimination rate 
constant from central compartment (K10), distribution rate constant from central 
compartment to peripheral compartment (K12), distribution rate constant from peripheral 
compartment to central compartment (K21) and volume of distribution of the central 
compartment (V1). No covariates were incorporated into the model. 1-compartmental PK 
model was also evaluated which deviated at the terminal phase. 
 
The final PK parameter estimates obtained from this model were shown in Table 6-2. 
Secondary parameters of α, β were also derived from estimated rate constants as 0.053 
min
-1
 and 0.0086 min
-1
 respectively. Most parameters showed a reasonable amount of 
inter-individual variability (≤40%) except K21. Goodness of fit plots of observed versus 
population and individual predicted concentrations were shown in Figure 6-5. The 
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observed versus population-predicted/individual-predicted plots showed a uniform 
distribution of the data points across the line of unity. Visual predictive check was also 
implemented and shown in Figure 6-6. The observed values were found to distribute 
appropriately within the (5-95%) range of the simulated data.   
 
2 compartmental model (iv.) 
Pi =TVP*EXP(ηi) 
Cobsij =Cij*EXP(εij), ε~ N(0, 0.01) 
Parameter Population 
estimate(%SE) 
Between subject 
variability (%) 
V1 (ml) 16.8753 (0.6364) 9.2 
K10 (1/min) 0.0454 (0.0706) 19.3 
K12 (1/min) 0.0065 (0.1583) 36.4 
K21 (1/min) 0.0101 (0.2464) 80.2 
Secondary parameters 
α (1/min) 0.053  
β (1/min) 0.086  
 
Table 6-2 Final PK parameter estimates obtained from 2-compartmental model for 
intravenous NAC in WT mice; secondary parameters of α and β were also calculated. 
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Figure 6-5 Goodness-of-fit graphics for NAC plasma concentration fitted with 2-
compartmental PK model. All values were transformed with natural log. (A), the 
observed concentrations versus the population predictions, (B) the observed 
concentrations versus the individual predictions. The line of identity is included in Figure 
3 (A) and (B).  
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Figure 6-6 Visual predictive check (VPC) for NAC plasma concentration fitted with 2-
compartmental PK model. Red lines: 5, 50 and 95
th
 percentile for observed 
concentrations; black lines: 5, 50 and 95
th
 percentile for simulated concentrations. 
Ideally, 90% of the observations should fall inside the 90% prediction interval. 
 
 
6.3.3 Labeled NAC boosts unlabeled GSH rather than labeled GSH in RBC 
 
The concentration of GSH in the plasma has been reported to be much lower than the 
concentrations in RBC (Pendyala and Creaven, 1995). To better investigate the change of 
GSH, we chose RBC as our target matrix to measure the change in total GSH because 
RBC is where the predominant GSH is stored. As proposed in Figure 6-1, there are 
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several hypotheses of how NAC boosts GSH concentrations. In order to differentiate 
these different pathways, we used stable-labeled NAC to track the labeled cysteine group 
of NAC in its biotransformation and disposition. 
 
In RBC lysates, total GSH, both unlabeled and labeled, reduced and oxidized, was 
detected simultaneously using our established LC/MS method. As shown in Figure 6-7, 
the baseline total unlabeled GSH was 1289±196 µg/ml and total labeled GSH was 
undetectable. Following dosing with NAC, the total unlabeled GSH was increased. The 
maximal concentration was 1579±86 µg/ml, with corresponding Tmax of 150 minutes 
post-dosing. It was a quite interesting finding that the unlabeled GSH was increased up to 
~290µg/ml (22.5% of baseline) following the administration of labeled NAC. The results 
indicated that NAC could boost the GSH levels through other pathways in addition to 
acting as cysteine prodrug for GSH synthesis.  
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Figure 6-7 Unlabeled(A) and labeled total GSH(B) levels detected in the RBC following 
NAC dosing in WT mice. Baseline levels prior to NAC dosing was presented by the red 
lines; Area under the curve above the baseline (AUCb) from 0-280 minutes were 
calculated and shown as well as the time for maximal concentration (Tmax).  
 
The baseline level for labeled GSH was found to be 0 µg/ml, since there was lack of 
stable labeled atoms endogenously. Following the administration of labeled NAC, labeled 
GSH was found to be increased (Figure 6-7) with a maximal concentration of 1.4±0.2 
µg/ml with corresponding Tmax of 30 minutes post-dosing. The concentration of labeled 
GSH quickly decreased to concentrations around the BLQ. The maximal increase in the 
labeled GSH was minimal (1.4 µg/ml) compared to the increase in unlabeled GSH (290 
µg/ml). Moreover, when we compared the area under the curve and above the baseline 
(AUCb) from 0 to 280 minute, the AUCb of labeled GSH was 341.5 µg∙ min∙ml-1 and 
that of unlabeled GSH was 58325.7 µg∙ min∙ml-1. The results indicated that boosting the 
  137 
unlabeled GSH was the major pathway for NAC mechanisms of action. In the following 
studies, we used the unlabeled GSH as the major PD endpoint and correlated the plasma 
concentrations of NAC with the unlabeled GSH. 
 
6.3.4 Population PK/PD analysis of NAC in plasma and total GSH in RBC 
 
Simultaneous PK and PD modeling on NAC/GSH were implemented with fixed 
population means, variance and covariance matrix of NAC PK parameters, which were 
previously derived from the population PK analysis. The PD model described in Figure 
6-3 was fitted using total GSH in RBC. A population PK/PD analysis was performed 
where the population means, variance and covariance matrix of V1, K10, K12, and K21 
were fixed (Table 6-2).  The population PD parameters estimates are listed in Table 3. Of 
note, the population mean for efficacy (Emax) was estimated to be 22.6% increase in the 
rate of GSH production. Between-subject variability for all parameters were estimated 
and found to be lower than 40.0%. The coefficient of variation for the random residual 
constant was fixed to be 10% based on assay variability to resolve the identifiability issue. 
The VPC revealed that the full model provided a reliable description of the data with 
good precision of structural model and variance parameter estimates.  Figure 6-9 shows 
the observed GSH in RBCs concentrations versus time, with the observed median (solid 
line) and the observed 5th and 95th percentiles (blue shaded area) overlaid.  The plot also 
shows results from the VPC as the simulated median (dashed line) and 5th and 95th 
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percentiles (lighter blue shaded area) overlaid.  Overall, simulated distributions were 
similar to the observed NAC concentrations. 
 
 
 
Table 6-3 NAC-GSH population PD parameters in WT mice estimated in ADAPT5. PK 
parameters were the same as in Table2. 
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Figure 6-8 Goodness-of-fit graphics for PD output (GSH in RBC) of NAC-GSH PK/PD 
modeling. Population PK parameters were fixed.  (A), the observed concentrations versus 
the individual predictions; (B), the observed concentrations versus the population 
predictions; (C), standardized residuals versus the time after dosing; (D) standardized 
residuals versus the individual predictions; the line of identity is included in both (A) and 
(B).  
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Figure 6-9 Visual predictive check (VPC) plots for NAC-GSH PK-PD model evaluation 
(total GSH levels were simulated). Observed data is similar to the simulated data in a 
reasonable way.  
 
6.3.5 Labeled NAC boosts redox ratios of unlabeled GSH/GSSG in brain 
 
In brain homogenates, NAC, unlabeled and labeled (on one cysteine residual) GSH, 
unlabeled and labeled GSSG were detected simultaneously using our established LC/MS 
method. Interestingly, no NAC was detected in brain homogenates which was consistent 
with previous findings that very limited amount of radio-labeled NAC could cross the 
brain-blood barrier (BBB) (Farr et al., 2003). In addition, we were not able to detect any 
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labeled GSH and GSSG products in brain homogenates (data not shown). Redox ratios of 
unlabeled GSH/GSSG in brain tissue homogenates were found to be increased after the 
administration of single intravenous bolus NAC (Figure 6-10). The baseline redox ratios 
(GSH/GSSG) in control group dosed with saline were 11.2± 0.9. Redox ratios were found 
be higher than the baseline levels at all sampling times post-dosing (5min -280 min) and 
the maximal redox ratio was found to be 19.5± 2.9 at 150 minutes post-dosing. Two 
peaks appeared over the sampling interval with a fast peak appeared at 15 min and a slow 
peak appeared at 150 min. These results indicated that intravenous bolus NAC increases 
the redox ratios in the brain for a sustained period of time and possibly via multiple 
mechanisms.  
 
 
Figure 6-10 Redox ratios (GSH/GSSG) in the brain post NAC dosing in WT mice. 
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6.4 Discussion 
 
NAC has long been considered as a potent antioxidant in eliminating free radicals or 
oxidative stress in clinical studies and this effect is thought to be related to its 
contribution towards the biosynthesis of GSH, which plays a key role in antioxidant 
defense system of cells. However, the precise mechanisms of action for the 
biotransformation of NAC into GSH are not clear. The present study was designed to 
identify the mechanisms of action of NAC in wild type (WT) mice using stable-labeled 
technology where the cysteine group on NAC molecule is labeled with non-radioactive 
isotopes so as to track its fate in biotransformation. As shown in Figure 6-7, the labeled 
GSH concentrations increased much less than the unlabeled GSH concentrations 
following a single intravenous  NAC dose. The AUCb (0-280 min) of labeled GSH was 
found to be less than 0.1% of unlabeled AUCb. These data suggest that only minimal 
GSH synthesis is the result of direct deacetylation of NAC to cysteine.  Based on these 
data, increased availability of free cysteine (Figure 6-1, pathway B) or increased free 
GSH (Figure 6-1, pathway C) might describe the role of NAC in GSH synthesis better 
compared to direct synthesis (Figure 6-1, pathway A).  However, this conclusion may 
only be valid in WT mice without GSH depletion. In in-vivo disease models with GSH 
depletion, endogenously- and exogenously-produced GSH may both play key roles in the 
antioxidative defense. 
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Despite the wide investigation of NAC’s effects on total GSH and redox ratios, the PK/ 
PD parameters of NAC and GSH have not been well characterized. The fact that NAC 
and GSH are present in both the reduced and oxidized forms makes the analytical 
methods quite complicated (Olsson et al., 1988).Olsson et al. showed that the PK 
parameters of reduced form NAC were quite different from total (reduced and oxidized) 
forms of NAC. Thus the method of analysis for NAC and GSH varied and might 
influence the PK study results (Cotgreave and Moldeus, 1987, Ercal et al., 1996, Zinellu 
et al., 2009). Our lab has established a standard LC/MS assay protocol to simultaneously 
measure the reduced, oxidized or total forms of NAC or GSH which was crucial for this 
study.  
 
We also characterized the PK parameters of NAC in WT mice. Consistent with previous 
results, the T 1/2 was estimated to be around 20 minutes using radio-labeled techniques 
(Farr et al., 2003) in mice. This T1/2 in mice was found to be much shorter than in cat (1.3 
hrs) (Buur et al., 2013), dog (4.0 hrs) (Shen et al., 2008) and human (2.3 hrs) (Borgstrom 
et al., 1986) which indicated that NAC was eliminated in mice very quickly. In addition, 
we also found out that a 2-compartmental model fitted the data pretty well, consistent 
with previous modeling work of NAC in dog (Shen et al., 2008) and cat (Buur et al., 
2013). In humans, 2-compartment and 3-compartment PK models were both 
implemented for intravenous NAC (Brown et al., 2004). However, the validity of the PK 
model is restricted by limited sampling time points in our study, especially at the terminal 
phase. Current NAC studies in murine disease models, such as ALD mouse model 
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(Lopez-Erauskin et al., 2011a), Parkinson’s mouse model (Park et al., 2004) and 
Alzheimer’s mouse model (Farr et al., 2003), lack PK analysis which would better 
characterize the therapeutic potential of NAC. Results from this study would greatly 
facilitate the PK/PD modeling of NAC in these disease models. 
 
NAC was reported to increase the intracellular GSH levels in RBCs in rats (De Flora et 
al., 1985) and peripheral blood lymphocyte in human (Pendyala and Creaven, 1995). The 
elevations in GSH was assumed to shed beneficial effects on various oxidative stress 
related disease conditions such as cancer patients receiving chemotherapy (Pendyala and 
Creaven, 1995) , or neurodegenerative disorders of Parkinson’s disease (Guo et al., 2013) 
and Alzheimer’s disease (Lasierra-Cirujeda et al., 2013). However, there is no PK/PD 
model established to describe the relationship between NAC and GSH as to our 
knowledge. In this study, we found out the indirect response model (or turnover model, 
Figure 6-11) (Dayneka et al., 1993) could be rationally used to describe the production 
process of intracellular GSH where NAC concentration was linked to stimulate the rate of 
GSH production through an Emax model (Figure 6-3). Our results indicated that the 
maximal increase in the rate of GSH production (Emax) was 22.6%. Given this result be 
extended to human due to similar pathways of mechanisms of action and enzyme 
properties, it could well explain previous published results that most human subjects were 
observed to have around 20% increase in GSH levels in peripheral blood lymphocyte 
post NAC dosing (Pendyala and Creaven, 1995).  
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Figure 6-11, basic indirect response model structure (left) and representative response 
variable time profile (right). Figure from (Dayneka et al., 1993). 
 
In addition, we also investigated the redox ratio changes in brain tissues as exploratory 
specific aim for this study. Redox ratios in the brain were reported as crucial indicator for 
oxidative stress (Escobar et al., 2013, Mishra and Srivastava, 2013). Using magnetic 
resonance spectroscopy (MRS) in Parkinson’s and Gaucher’s patients and healthy 
volunteers, Holmay et al. discovered that brain GSH was boosted in all tested subjects 
following a single intravenous administration of 150mg/kg NAC (Holmay et al., 2013). 
In this study, we further tested the redox ratios in the brain tissues following the same 
dose of NAC in mice. Redox ratios were found to be greatly increased. Although the T1/2 
of NAC in plasma was 24.5 minutes as shown in Table1, the redox ratios were sustained 
for the later time points when NAC was undetectable in plasma. The results indicated 
delayed and sustained effect of intravenous bolus NAC to boost brain redox ratios. The 
fact that there was very limited NAC, if any, crossed the blood-brain-barrier indicated 
that NAC may not need to be taken up into the brain to boost redox ratios. It is well-
known that the amount of cysteine is highly correlated with the GSH/GSSG redox ratios 
(Dayneka et al., 1993), and that NAC could release free cysteine quickly and significantly 
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(Radtke et al., 2012). Thus it is highly possible that NAC increases GSH/GSSG redox 
ratios by increasing free cysteine available in the brain. 
 
However, due to the limitations in experimental design with destructive sampling 
techniques, as well as limited animals per group and lack of sampling time points after 3 
hours, large amount of variability was observed in both PK and PK/PD modeling studies. 
Further studies using large animals with more intensive sampling time points could 
greatly improve the PK/PD model and generate better understanding of the mechanisms 
of action of NAC.   
 
In the current study, ~20g C57 mice were administered with a single dose of 150 mg/kg 
NAC intravenously.  The plasma NAC concentration immediately following dosing 
(maximal) was estimated to be180 µg/ml, and the T1/2 was estimated to be 25 minutes. 
Previously, our lab had collected PK data in CCALD patients dosed with 70mg/kg every 
6 hrs intravenous NAC (Holmay et al., 2012). The maximal concentration for plasma 
NAC was found to be ~100 µg/ml and the T1/2 was estimated to be 1.5hrs in patients. The 
plasma concentrations studied in mice and CCALD patients are comparable except that 
NAC is eliminated more quickly in mice than in patients. Conclusions from this mice 
study can be also applicable to CCALD patients. 
 
6.5 Conclusion 
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In summary, the present study characterized the PK properties of NAC in mice, 
established the PK/PD model between plasma concentration of NAC and GSH levels in 
RBCs, and explored the effect of NAC administration on redox ratios in the brain. 
Further, this study investigated the biotransformation of NAC and proved that increased 
GSH mainly came from endogenous source instead of exogenous source using stable-
labeled NAC. 
 
Our long-term research goal is to understand, develop, and refine dosing strategies for 
NAC in oxidative stress related CNS disorders such as Parkinson’s and Gaucher’s disease. 
Our understanding of the mechanisms of action of NAC and results from this study 
provide target concentrations that will inform the design of NAC dosing strategies in 
future studies in disease mouse models and clinical studies. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE STUDIES 
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7.1 Summary and conclusions 
 
CCALD is one type of neurodegenerative disorders and assumed to be highly associated 
with oxidative stress in recent studies. The successful application of NAC in CCALD 
patients during HSCT is the main drive for design of experiments in current research. The 
main goal of this study is to investigate in vitro, in vivo and clinical pharmacology of 
NAC in mitigating oxidative stress in CCALD patients. Projects in the thesis include a 
clinical study to find out the downstream antioxidant proteins induced by NAC in 
CCALD patients (Chapter 3), an in-vitro cell study to examine the mechanisms of action 
of NAC in promoting cell survival under oxidative stress (Chapter 4), an in-vitro cell 
study to investigate the roles of NAC in reversing the mitochondrial toxicity induced by 
VLCFAs associated with CCALD disorders (Chapter 5), and an in-vivo mice study to 
characterize the PK/PD properties of NAC as well as its transformation pathways into 
GSH (Chapter 6).  
 
Major conclusions from all studies above are summarized below: 
a) The clinical and in-vitro studies (Chapter 3 and 4) led us to conclude that HO-1 
is a potential mediator for NAC cytoprotective action in addition to the well-
known GSH.  
b) HO-1 and ferritin induced by NAC are highly correlated in plasma of CCALD 
patients (Chapter 3). 
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c) NAC promotes cell survival under oxidative stress through HO-1 and GSH 
(Chapter 4).  
d) VLCFAs, which are thought to be the primary cause for CCALD disease, cause 
mitochondrial dysfunction in oligodendrocytes. In particular, VLCFAs deplete 
mtGSH and therefore increase levels of superoxide anions in mitochondria 
(Chapter 5).  
e) NAC restores mtGSH depleted by VLCFAs and reverses the mitochondrial 
toxicity caused by VLCFAs (Chapter 5).  
f) PK/PD studies in mice showed that intravenous administration of NAC could 
increase the total GSH in RBCs and redox ratios in brain (Chapter 6). 
g) Tracking the biotransformation of stable-labeled NAC revealed that NAC 
increases GSH levels through increasing the availability of endogenous cysteine 
or releasing GSH from oxidized forms, rather than providing the exogenous 
cysteine as substrates for GSH synthesis (Chapter 6).  
 
In summary, we investigated the pharmacology of NAC using different biological 
systems including mitochondria, cells, mice and human patients. NAC was shown to 
mitigate oxidative stress in CCALD associated models by supplementing GSH and 
increasing the expression of HO-1. In addition, NAC was also shown to be effective at 
the site of brain which is extremely meaningful to neurodegenerative disorders with CNS 
dysfunction such as CCALD. 
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7.2 Significance 
 
NAC has been investigated extensively in various disease conditions. The current studies 
target to provide more information for the application of NAC in the treatment of 
CCALD. Although NAC has become the standard of care for late-stage CCALD patients 
during HSCT, the application of NAC in the early-stage of CCALD or in other clinical 
phenotypes of ALD such as AMN has not been validated and studied extensively. In 
addition, NAC may also benefit other types of neurodegenerative disorders associated 
with oxidative stress. Full understanding of the mechanisms of action of NAC is therefore 
quite meaningful in promoting the use of NAC into neurodegenerative disorders sharing 
similar pathologies such as Gaucher's disease, Multiple Sclerosis, Alzheimer's disease 
etc. 
 
Significance of studies performed in this thesis is summarized below: 
a) Studies indicate HO-1 as the newly discovered downstream mediator for NAC’s 
mechanisms of action (Chapter 3 and 4). 
b) Results from the thesis show for the first time that depletion of mtGSH is one of 
the pathological mechanisms in CCALD and that targeting mitochondrial 
dysfunction may be a potential intervention strategy for CCALD patients (Chapter 
5). 
c) PK/PD models are generated for the first time to describe the role of NAC in 
vivo. And that the biotransformation of NAC is clarified (Chapter 6).  
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d) Characterization of NAC mechanisms of action can help to optimize therapy in 
late-stage CCALD patients. GSH levels, redox ratio, HO-1 and ferritin levels can 
serve as new biomarkers assessing NAC therapy. These biomarkers can guide 
dosing regiments including dose and route of administration. 
e) The information generated from my study on the efficacy of NAC in CCALD is 
also applicable to other neurodegenerative disorders sharing similar pathologies 
such as Gaucher's disease, Multiple Sclerosis, Alzheimer's disease etc. 
 
In summary, results from this thesis will advance the use of NAC by providing a clearer 
understanding of its pharmacology. Information from the studies will help to explain the 
results of past clinical trials and, prospectively, be used to design studies aimed at 
determining optimal NAC dosage regimens. 
 
7.3 Future studies 
 
The fact that NAC improves the survival in late-stage CCALD patients makes the use of 
NAC promising. Understanding of its mechanisms of action can greatly facilitate its use 
in other disease conditions. From conclusions drawn from current research, use of NAC 
in early-stage CCALD is possibly beneficial, as well as in other types of 
neurodegenerative disorders. However, clinical trial is the golden standard to verify and 
extend conclusions from in-vitro and in-vivo studies to patients. Future studies will be 
required to examine the efficacy of NAC on mitigating oxidative stress in different stages 
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of CCALD, other types of ALD, and other neurodegenerative disorders associated with 
oxidative stress.  
 
In addition, there are still unanswered questions on the use of NAC in neurodegenerative 
disorders, e.g., whether oral NAC is as equivalent as intravenous NAC in mitigating 
oxidative stress in neurodegeneration. And if it is true, substitution of intravenous 
formulation with oral formulation could greatly reduce the cost given the fact that 
cheaper NAC tablet is available on market. In addition, NAC could be used in 
combination with other antioxidants, which could possibly generate synergistic beneficial 
effects due to various mechanisms of antioxidant action. 
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